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ABSTRACT
MOLECULAR AND BEHAVIORAL STUDIES IN CDKL5 DEFICIENCY DISORDER
Ethan Schroeder, Ph.D.
University of Nebraska Medical Center, 2020
Supervisor: Jyothi Arikkath, Ph.D.
CDKL5 Deficiency Disorder (CDD) is an X-linked neurodevelopmental disorder
associated with epilepsy, developmental retardation, autism, and related phenotypes.
Currently, there is no cure available for the disorder. Thus, the identification of cellular
and molecular aberrations in this disorder and the generation and validation of mouse
models that recapitulate core aspects of the disorder are a pressing need in the field.
Our studies are aimed at filling this gap.
Mutations in the CDKL5 gene, encoding CDKL5, have been identified in this
disorder. CDKL5 is a protein with homology to the serine-threonine kinases and
incompletely characterized function. Mutations in CDKL5 are predominately localized in
the kinase domain of the protein, suggesting that a compromise of the kinase activity is a
key component of the pathology of the disorder.
Our data indicate that genetic loss of CDKL5 in glutamatergic or GABAergic
neurons of the cortex and striatum, respectively, in murine models differentially alters
expression of some components of the mechanistic target of rapamycin (mTOR)
signaling pathway and synaptic markers in a neuron-type specific manner. Thus, loss of
CDKL5 leads to molecular aberrations that are specific to neuronal subtypes in the
cortex and striatum. Further, our studies indicate that a mouse model bearing a human
CDD mutation that does not result in a protein-null phenotype recapitulates core
behavioral aspects of the disorder, including motor and learning impairments and may
be a good model for the disorder.

Taken together, these studies identify some molecular aberrations that underlie
CDD and validate a mouse model for CDD. Future studies can be directed at correcting
these aberrations and taking advantage of the CDD mouse models to identify and
correct other molecular deficits that can be targeted pharmacologically, thus paving the
way for therapy in this devastating disorder.
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INTRODUCTION
Genetic Basis of CDKL5
CDKL5 deficiency disorder (CDD) is a neurodevelopmental disorder associated
with a variety of debilitating phenotypes including autism, epilepsy, and motor and
intellectual deficits. CDD is X-linked with females affected more often than males(1).
Phenotypes are comparable between males and females though symptoms may be
more severe in males(2-5). This is similar to other X-linked dominant disorders, such as
Rett Syndrome, in which the increased severity in males results in miscarriage or infant
death, though this mechanism has not been reported in the literature. Of note, mutations
in CDKL5 are de novo, though parental mosaicism(6) and asymptomatic family
members(7) have been observed. Mutations in CDKL5(8, 9), encoding CDKL5, occur in
roughly 1:40,000-1:60,000 live births and underlie the disorder(10, 11). Nearly 300
mutations have been reported, of which over two-thirds are nonrecurrent(12). Mutations
span the full-length of CDKL5 and variants are classified into four groups: absence of
functional protein, missense in the kinase domain, truncating between amino acids 172781, and truncating between amino acids 781-905(13). In this chapter, we discuss our
current knowledge of CDD and CDKL5.
Gene Expression and Protein Localization Patterns
Gene
Cyclin-dependent kinase-like 5 (CDKL5) is a serine/threonine kinase encoded by
the CDKL5 gene located at Xp22.13 in humans, where it is subject to X-inactivation. Ten
isoforms have been identified between humans and rodents. Numeric values in the
nomenclature indicate orthology between species, while alphabetical designations
specify species.
Human
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The CDKL5 gene has five human isoforms with multiple splice sites, exons, and
transcription start sites(14). Isoforms hCDKL5_1-4 are expressed at higher levels in the
adult brain than the fetal brain, with hCDKL5_1, previously termed CDKL5107(15), the
dominant brain isoform. This isoform contains 18 coding exons. hCDKL5_2 differs from
hCDKL5_1 in that it contains exon 17. Isoforms hCDKL5_3&4 are identical to isoforms
hCDKL5_1&2, respectively, but contain a cryptic splice site in exon 11 resulting in a
protein 17 amino acids shorter. hCDKL5_2,3&4 are widely expressed but of lower
abundance than hCDKL5_1. hCDKL5_5 utilizes alternative splicing in exon 19 and is the
only isoform to contain exons 20-22. It is more abundantly expressed in the fetal brain
than the adult and is most predominant in the testis.
Mice
Mice also have five Cdkl5 isoforms with mCdkl5_1&2 orthologous to their
respective human isoforms. Similar to the human isoforms, mCdkl5_1 is the dominantly
expressed brain isoform. mCdkl5_1&2 are expressed in mouse brains in a
developmentally increasing pattern, with some RNA detected at embryonic stages.
Conversely, mCdkl5_8 is highly expressed at embryonic stages and lowly expressed in
the adult(14). Exon 17, which was previously described as exon 16a(16) or 16b, is found
primarily in the brain of mice, with olfactory bulb levels most similar to wild-type Cdkl5
levels(17).
Rat
The predominant brain isoform in rat, rCdkl5_1, is orthologous to the human and
mouse brain-dominant isoforms and similarly contains 18 exons(18). rCdkl5_9&10 were
previously discovered as CDKL5a & b, of which CDKL5a is predominantly expressed in
the brain. Both isoforms persist in the rat cortex until at least P14(19) and contain
different 3’-exons from other human or mouse isoforms.
Zebrafish
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CDKL5 is also expressed in zebrafish with two splice variants. The short form of
zCDKL5 that excludes exon 16 is expressed in many tissues, while the long form is the
predominant brain form. The long form of zCDKL5 is expressed beginning 12 hours
postfertilization(20). CDKL5 transcripts in zebrafish are expressed in a spatiotemporal
manner similar to that in humans(21).
In summary, multiple transcripts of CDKL5 are generated by alternative splicing.
Brain predominant isoforms, CDKL5_1&2 are orthologous between human, mouse, and
rat. This homology poses rodent model study as a means for understanding the human
disorder.
Wild-type Protein
CDKL5 is a protein of 107 kDa encoded by 960 amino acids for the brain isoform,
hCDKL5_1. Originally named STK9, serine/threonine kinase 9, due to homology with
other serine/threonine kinase subfamily proteins, CDKL5 contains a kinase domain that
shares homology with MAPK-family and CDK-family proteins(22). CDKL5 contains an Nterminal kinase domain with nuclear import and export signals localized within the Cterminal. While CDKL5 is expressed in a variety of tissues, it is enriched in the brain,
with highest levels observed in the cortex, hippocampus, and striatum, areas relevant to
the clinical phenotype of the disorder(23, 24). CDKL5 levels in the hippocampus, cortex,
and cerebellum increase throughout early development (E18.5, P7, P10)(25) and remain
in adult (P120) mice(26). The prefrontal cortex is functionally associated with higher
cognitive function and the hippocampus with working memory. Amongst many functions,
the striatum has a role in facilitating voluntary movement.
Beyond rodents, CDKL5 is also expressed is several cell lines(27). CDKL5 has
homology in other species that may provide additional models for study. In these
models, Chlamydomonas(28) and C. elegans(29), CDKL5 localizes in cilia and flagella.
Within the brain CDKL5 is highly expressed in neurons with lower expression in glia(26).
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Subcellularly within neurons, CDKL5 is expressed in both the nucleus and cytoplasm(26,
27). The nuclear and cytosolic localization is observed in both glutamatergic and
GABAergic neurons in the hippocampus(30). The subcellular distribution of CDKL5
varies between brain regions in the adult mouse. Fractionated whole brain mouse
lysates show an increase in nuclear CDKL5 levels around P14, in a pattern similar to the
developmental expression of CDKL5(26). Within the nucleus, CDKL5 localizes in nuclear
speckles, sites for RNA splicing, of DIV10 hippocampal neurons and NIH3T3 cells(31).
CDKL5 also localizes primarily in the nucleus of peripheral blood mononuclear, PBMCs,
and lymphoblastoid cells in both male and female humans(32).
The C-terminus of CDKL5 mediates cytoplasmic localization in HeLa cells via an
indirect-leptomycin-B, a nuclear export inhibitor, mechanism(26), however, it is not clear
if similar determinants regulate the nuclear localization of CDKL5 in neurons. Despite
localization in both the nucleus and cytosol, CDKL5 does not shuttle constitutively
between the two compartments under endogenous conditions. Glutamate, an excitatory
neurotransmitter, induces a perinuclear translocation of CDKL5 that is dependent on
extrasynaptic NMDARs(30), in mouse hippocampal neurons. Co-expression of CDKL5
and Mind bomb 1(Mib1), a ubiquitin ligase that regulates neuronal morphogenesis and
synaptic activity in postmitotic neurons, in HEK293 cells results in translocation of
CDKL5 from the nucleus to colocalizing in cytoplasmic puncta(33). Furthermore, the less
dominant brain form of CDKL5, CDKL5_2, localizes in the cytosol similar to wild-type in
COS7 cells, and shifts to the nucleus with leptomycin-B treatment(17). In summary,
CDKL5 localizes in the nucleus and cytoplasm in both nonneuronal cells and in neurons.
The nuclear and cytoplasmic localization can be influenced by neuronal activity.
In addition to the nucleus and soma, Cdkl5(34) and CDKL5(35) is expressed in
the synaptosome in the mouse brain suggesting that at least a fraction of CDKL5 may be
generated by local translation at the synapse.
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In DIV15 mouse hippocampal neurons, CDKL5 is localized at excitatory but not
inhibitory synapses , as it colocalizes in dendritic spines with PSD-95, postsynaptic
density protein 95, an excitatory postsynaptic marker, and VGluT1, vesicular glutamate
transporter 1, an excitatory presynaptic marker, but not gephyrin, an inhibitory
postsynaptic marker, or VGAT, vesicular GABA transporter, an inhibitory presynaptic
marker(35). Together, CDKL5 transcript and protein localize in the postsynaptic density
of excitatory synapses and a fraction of the protein is generated by local synaptic
translation.
Localization of CDKL5 is also influenced by catalytic activity and the C-terminus
in NIH3T3 and HEK293 cells(36).
CDD Forms of CDKL5
The repertoire of CDD mutations include point mutations, splicing variants, and
frameshift mutations. While a wide variety of mutations are known, several are localized
within the kinase domain. Several of these mutant forms generate protein and are not
protein-null mutations. Expression of CDD forms of CDKL5 in heterologous cells and
neurons indicates that several of these mutant forms have perturbed localization.
N267KfsX271, a two base pair deletion resulting in a stop codon at amino acid 271, is
primary cytoplasmic in COS7 cells, while S438QfsX471, a single base pair duplication
resulting in a stop codon at amino acid 471, is primarily nuclear and L879EfsX908, a two
base pair deletion resulting in a stop codon at amino acid 908, is perinucleuarpunctate(37). A40V and L220P are mislocalized to primarily the cytoplasm when
overexpressed in COS7 cells(38). Overexpression of the R175S CDKL5 point mutation
in NIH3T3 cells causes disruption of nuclear speckles though not to the same extent as
wild-type CDKL5(31). In transfected neurons, E570X CDKL5 is mislocalized from
dendritic spines to the soma and dendritic shaft, relative to wild-type, while CDKL5
missing amino acids 1-670 was localized similar to wild-type(39). Collectively, some
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human pathogenic mutations localize differently than wild-type CDKL5, suggesting a
mechanism for impaired CDKL5 functions in CDD.
Neuronal Functional Roles of CDKL5
Consistent with the expression pattern of CDKL5 in neurons, several neuronal
functional roles of CDKL5 have been identified. More importantly, several of these
functional roles are disrupted by CDD mutations, suggesting possible mechanisms that
lead to the molecular pathology of CDD.
Kinase Functional Roles
As mentioned previously, CDKL5 contains an N-terminal kinase domain from
amino acids 13-297. Within the kinase domain, CDKL5 contains a TEY motif in the Tloop. In other MAPKs and CDKs, phosphorylation of this motif by upstream kinases or by
autophosphorylation, activates the kinase(40-42).
Identification of CDKL5 Substrates Using an Unbiased Approach
Since the kinase domain is a key feature of CDKL5, two separate studies have
taken an unbiased approach to identify the substrates of CDKL5. To identify possible
substrates, CDKL5 in U202 osteosarcoma cells was knocked down using Crispr/Cas9
and re-expressed using the Flp-In T-Rex system. The knockout and corresponding reexpression avoids clonal differences between knockout and parental cells. To identify
proteins whose phosphorylation was impacted by loss of CDKL5 and could be likely
kinase substrates for CDKL5, lysates from these cells were enriched for
phosphoproteins and analyzed by mass spectrometry(43).
The most highly enriched phosphomotif was RXXS. The most changed hits
besides CDKL5 itself were MAP1S S900 and CEP131 S35. MAP1S, microtubule
associated protein 1S, has roles in microtubule dynamics(44-47), and CEP131,
centrosomal protein 131, has roles in centriolar satellites for cilia formation(48, 49).
These two sites have sequence similarity, RPLSA and RPGSA, respectively, indicating
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that CDKL5 may have preference for residues with the sequence RPXSA. Other
identified proteins include DLG5(50, 51), discs large homolog 5, CENPC, centromere
protein C, and NUSAP1, nucleolar and spindle-associated protein 1. Collectively, these
proteins are involved in cytoskeleton or cilium-related processes(43).
Further validation studies indicate that these proteins are indeed direct
substrates of CDKL5. HEK293 cells expressing CDKL5 and MAP1S or CEP131 or DLG5
confirmed CDKL5 is able to phosphorylate MAP1S at S900, CEP131 at S35, and DLG5
at S1115. To confirm that MAP1S and CEP131 are direct substrates, peptides of their
phosphomotifs were incubated with CDKL5 and quantified from kinase assays. Both
peptides are robustly phosphorylated, while peptides from other proteins from the mass
spectrometry screen are not. Through amino acid substitutions and phosphorylation
assays, the motif RPX(S/T)(A/G/P) was determined to be preferred by CDKL5.
As mentioned previously, CDKL5 contains a TEY motif, that must be
phosphorylated in CDKs and MAPKs for them to be active. To test whether this is also
the case for CDKL5, CDKL5 was expressed in HEK293 cells and immunoblotted with
phopho-tyrosine antibodies. CDKL5 was found to autophosphorylate on Y171, though it
cannot phosphorylate tyrosine on other peptides. CDKL5 with mutated Y171 is not able
to phosphorylate MAP1S or CEP131 in vitro(43). Additionally, lysates from HEK293T
cells transfected with FLAG-tagged constructs indicate C-terminal truncated CDKL5
displays higher autophosphorylation levels and higher phosphorylated TEY than fulllength CDKL5(27). Together this indicates that CDKL5 autophosphorylates and this TEY
phosphorylation is necessary for activation of CDKL5 kinase activity towards substrates.
Kinase activity of CDKL5 has also been shown to alter splicing. Using RT-PCR
and the Adenovirus E1A minigene, overexpression of GFP-CDKL5 WT resulted in an
alternative splicing products, while overexpression of the kinase dead mutant, GFP-
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CDKL5 K42R was similar to the control splicing pattern(31). The mechanisms that
underlie this functional role of CDKL5 remain to be understood.
Thus, the kinase activity of CDKL5 is functional and phosphorylates MAP1S,
CEP131, and DLG5, all of which have key roles in neuronal morphogenesis and
function. Furthermore, CDKL5 autophosphorylates on Y171 and this residue must be
phosphorylated for CDKL5 kinase activity. While these studies were performed in
nonneuronal cells, CDKL5 kinase function has also been assessed in neurons.
Since the majority of CDD mutations are localized in the kinase domain (aa 13297), perturbations of the kinase activity have been suggested to be one of the
mechanisms that contribute to the pathology of CDD. In assays similar to those
described previously, CDKL5 pathogenic mutations G20D, L64P, I72T, R178W, and
Q219P, all localized in the kinase domain, all reduce phosphorylation of MAP1S and
CEP131. Furthermore, the G20D and L64P mutations reduce CDKL5
autophosphorylation(43). Another mutation, S215R, reduces MAP1S and CEP131
phosphorylation levels in HEK293 cells(52). Furthermore, the pathogenic mutation
R175S(53) and C-terminal truncation at amino acid 781 retain autophosphorylation
capability, while kinase dead mutants, K42R and C152F, do not(36). However, R175S
CDKL5 has also been shown to be catalytically dead(27). Thus, the kinase domain of
CDKL5 is a critical functional domain and promotes phosphorylation of multiple
substrates with key roles in neuronal architecture and function. Functional impairments
in this domain are observed with CDD mutations and may contribute to the pathology of
CDD.
Identification of Substrates via a Candidate-based Approach
Based on the initial characterization of CDD as an atypical form of Rett
Syndrome, a syndrome associated with mutations in MeCP2, methyl CpG-binding
protein 2, CDKL5-MeCP2 interactions have been examined. MeCP2 regulates gene
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activity through chromatin modification. CDKL5 autophosphorylates and mediates
MeCP2 phosphorylation in vitro(25, 36). This phosphorylation may occur indirectly
through other factors, as CDKL5 and a truncated form have also been shown to not
phosphorylate MeCP2(27). Despite uncertainty in the contribution of CDKL5 to MeCP2
phosphostatus, in HEK293T cells, CDKL5 interacts with MeCP2 in vitro via GST pulldown assays and in vivo via coimmunoprecipitation assays(25), while the C-terminal
truncated form does not, likely due to mislocalization(27). Both of these forms of CDKL5
neither associate with nor phosphorylate ARX, a gene associated with the development
the of West Syndrome, a syndrome with overlapping characteristics to both CDD and
Rett Syndrome. MeCP2 binds to CDKL5 at CpG rich sites and is associated with the
promoter of CDKL5. In ChIP assays from rat striatum, chronic cocaine exposure
increased MeCP2 binding to CDKL5(54). Of note, the ability of CDKL5 to phosphorylate
MeCP2 was not examined from an unbiased approach.
Another substrate of CDKL5 is Dnmt1, DNA methyltransferase 1, an enzyme that
methylates hemimethylated CpG after DNA replication. CDKL5 binds to Dnmt1 via Cterminal amino acids 651-938(55, 56). Furthermore, CDKL5 phosphorylates Dnmt1 in a
DNA-dependent manner, while CDKL5 phosphorylates MeCP2 in a DNA-independent
manner(55).
Amphiphysin 1, a protein involved in clathrin-mediated endocytosis, is
phosphorylated in the presence of the N-terminus of CDKL5. Amph1 appears to be more
strongly phosphorylated than other in vitro substrates: MeCP2 and Dmnt1. CDKL5
incubated with purified mutated Amph1 and assessed by kinase assay identifies S293 to
be the site of Amph1 phosphorylation by CDKL5 in mice, while in zebrafish both S285
and S293 are phosphorylated(20). Phosphorylation of Amph1 at S293 inhibits binding to
endophilin, another clathrin-mediated endocytotic protein, but not to Amph1 itself. Point
mutations in CDKL5, C152F, R175S, and P180L, do not retain the ability to
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phosphorylate Amph1, MeCP2 or Dmnt1(53), consistent with the requirement of a
functional kinase domain for activity. Furthermore, an in vitro kinase assay showed that
a mutant form of CDKL5, Y177C, does not phosphorylate known targets, MeCP2,
Dmnt1, or Amph1, nor does it autophosphorylate(57). CDKL5 has also been shown to
alter MAP3K5, a mitogen-activated protein activated by Rac1, mRNA levels in SH-SY5Y
cells when CDKL5 was knocked down with shRNA(58). From the striatal proteome of the
postsynaptic density of Shank3 knockout mice, CDKL5 was identified(59). Together,
CDKL5 phosphorylates Dnmt1, Amph1, and MeCP2, while in zebrafish only Amph1 is a
substrate, while MAP3K5 and Shank3 are potential substrates.
CDKL5 as a Substrate
CDKL5 is phosphorylated itself by other proteins. GST-DYRK1A, dual specificity
tyrosine-phosphorylation-regulated kinase 1A, phosphorylated a kinase deficient form of
CDKL5 in vitro and pulled down CDKL5. Similar to CDKL5, DYRK1A is a
serine/threonine kinase with roles in neurodevelopment(60). The site of CDKL5
phosphorylation by DYRK1A was identified as S308. Co-transfection of DYRK1A and
CDKL5 in Neuro2a cells resulted in a translocation of CDKL5 from primarily the nucleus
to primarily the cytoplasm. When transfected in Neuro2a cells, the phosphodeficient form
of CDKL5 (S308A) localized primarily to the nucleus, while the phosphomimetic form
(S308D) localized primarily to the cytoplasm, indicating that the residue S308 regulates
cellular localization(61).
In summary, CDKL5 has a kinase domain that can autophosphorylate. Dnmt1,
Amph1, MAP1S, CEP131, and MeCP2 are substrates for CDKL5, while CDKL5 is a
substrate for DYRK1A. Some mutant forms have impaired kinase activity, while the
R175S mutation may retain the ability to autophosphorylate.
Dendritic Arborization & Regulation
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CDKL5 has been shown to have a role in regulating the dendritic arbor. In
neurons, dendrites bear synapses and are the major site of information input into
neurons. Thus, dendritic arbor alterations can significantly impact neural circuit formation
and function(62).
Knockdown of CDKL5 in cortical rat neurons shortens dendrites and axons, and
expression of an shRNA resistant form of CDKL5 rescues the altered morphology both
in vitro and in vivo via in utero electroporation(19). Overexpression of CDKL5 enhances
dendritic arborization, however, overexpression of a kinase dead form of CDKL5 (K42R),
or with CDD mutant constructs (C152R and R175S), or deletion of the C-terminus, does
not lead to as robust enhancement of the dendritic arbor as the wild-type protein. Thus,
CDKL5 promotes dendrite arborization and CDD mutants perturb these functional
effects.
In NIH3T3 cells, stimulation with PDGF, platelet-derived growth factor which acts
as a mitogen for nervous system cells by rearranging actin filaments, resulted in a
colocalization of CDKL5 and Rac1 in membrane ruffles(19). Rac1 is a member of the
small GTPase family of proteins with critical roles in axonal and dendritic
development(63) via its interaction with the actin cytoskeleton. PDGF stimulation of
COS-7 cells increased the interaction between CDKL5 and Rac1. In neurons CKDL5
localizes with F-actin, via phalloidin staining, in growth cones. BDNF, brain-derived
neurotrophic factor, a neurotrophin, with roles in dendrite arborization(64-66), stimulation
increased CDKL5 and Rac1 interaction in cortical neurons(19). The ability of CDKL5
knockdown or overexpression to regulate dendrites can be rescued by co-expressing
Rac1 or a dominant negative form, respectively. Thus, Rac1 is downstream of CDKL5 in
regulating dendrite morphogenesis. A likely upstream factor is BDNF. In DIV1 rat cortical
neurons, BDNF promotes the activation of Rac1 in a CDKL5-dependent manner. BDNF
treatment promotes the phosphorylation of CDKL5 phosphorylation that can be inhibited
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with the Trk tyrosine kinase inhibitor K252a with a time course correlating with Rac1
activation(19). Thus, CDKL5 is a key regulator of dendrite morphogenesis, likely
downstream of BDNF and CDD mutations impair its ability to regulate the dendritic
arbor.
Microtubule Regulation
IQGAP1, IQ-domain GTPase-activating protein 1, an effector of Rac1, and the Cterminus of CDKL5 coimmunoprecipitate with each other from P7 brains and HeLa cells.
In COS7 cells transfected with GFP-IQGAP1, endogenous CDKL5 is superimposed to
IQGAP1. HeLa cells silenced for CDKL5 with siRNA and scratched show reduced signs
of healing after 24h. IQGAP1 accumulates at the leading edge of the scratch. In COS7
cells silenced for CDKL5, the leading edge accumulation of IQGAP1 is not apparent.
COS7 cells silenced for CDKL5 and later transfected with CDKL5 and a kinase dead
mutant, K42R, show partial rescue of IQGAP1 localization to the leading edge with wildtype CDKL5 but not the kinase dead mutant. HeLa cells silenced for CDKL5 and
immunoprecipitated for IQGAP1 show reduced levels of Rac1 pulled down. Furthermore,
immunoprecipitation of cytoplasmic linker protein 170 (CLIP170), a plus end tracking
protein that facilitates microtubule growth(67), in cells silenced for CDKL5 shows
reduced levels of IQGAP1, indicating that CDKL5 regulates the IQGAP1/Rac1/CLIP170
complex. COS7 cells silenced for CDKL5 show a reduction in the length and lifetime of
CLIP170 comets. CLIP170 accumulates at the plus end of microtubules forming cometlike structures. A decrease in fluorescence in comets indicates microtubule
dissociation(68) or more specifically a reduced binding capacity of CLIP170 to
microtubules. Treating COS7 cells that were silenced for CDKL5 with pregnenolone, a
regulator of microtubule dynamics by restricting CLIP170 in its active conformation,
results in rescue of CLIP170 length and lifetime. Treatment of hippocampal neurons
silenced for CDKL5 with pregnenolone shows a polarization and axon length similar to
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wild-type while vehicle treated or progesterone treated cells shows a reduction(69). In
summary, CDKL5 interacts with IQGAP1 in a kinase-dependent manner. Loss of CDKL5
also affects other partners of IQGAP1, namely Rac1 and CLIP170 and IQGAP1 function.
Treatment of neurons knocked out for CDKL5 with pregnenolone results in restoration of
neuronal polarity and axon length, indicating pregnenolone may be a viable option in the
treatment of CDD.
Few CDD mutations have been studied in patient-derived cells. One such
mutation, CDKL5 R59X has been briefly examined in patient-derived fibroblasts. When
subjected to cold-induced stress, these fibroblasts show no difference in polymerized
microtubules compared to wild-type. This differs from MeCP2(70), indicating that despite
potential CDKL5-MeCP2 interactions, functional mechanisms are likely different and,
therefore, pathology of the associated disorders is also likely different.
Synaptic Functional Roles
Within dendritic spines of DIV18 rat hippocampal neurons, CDKL5 colocalizes
with PSD-95, postsynaptic density protein 95. CDKL5 and PSD-95 coimmunoprecipitate
each other from rat synaptosomes(39). Treatment of neurons with 2-BP, a palmitoylation
inhibitor, decreases the interaction of PSD-95 and CDKL5 via coimmunoprecipitation,
indicating that the PSD-95-CDKL5 interaction is palmitoylation dependent. Rat
hippocampal neurons transfected with GFP-PSD-95 colocalize with CDKL5 in puncta,
while a palmitoylation-deficient mutant does not, further supporting a palmitoylationdependent interaction. Knockdown of PSD-95 using shRNA reduces CDKL5 synaptic
levels, as does treatment of neurons with 2-BP. To identify the binding site of CDKL5 on
PSD-95, a GFP-PSD-95 derivative for amino acids 1-19 was used to
coimmunoprecipitate Flag-CDKL5 from HEK293T cells, indicating the first 19 amino
acids are necessary for binding to CDKL5. Flag-CDKL5 does not coimmunoprecipitate
palmitoylation-deficient PSD-95 or mutated N-terminal PSD-95(39). When co-expressed
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in COS7 cells CDKL5 and PSD-95 colocalize in puncta that are not present when
CDKL5 is co-expressed with a palmitoylation-deficient PSD-95. Immunoprecipitation of
GFP-PSD-95 from HEK293T cells is impaired with CDKL5 mutant constructs, E570X
and Q834X, relative to WT-CDKL5. Immunoprecipitation of PSD-95 by a mutated form of
CDKL5 missing amino acids 1-670 indicates the PSD-95-CDKL5 interaction is
dependent on the presence of the C-terminus. Furthermore, spine density is altered in
DIV8 rat hippocampal neurons and P14 cortex transfected with the 670 N-terminus
amino acid deletion(39). PSD-95-CDKL5 binding is reduced in acute mouse forebrain
slices when treated with NMDA. NMDA results in a calcium influx that activates CaM,
calmodulin. CaM binds to the N-terminal of PSD-95, blocking its palmitoylation, which is
required for its binding to CDKL5. This impairment is prevented with pretreatment of
calmodulin antagonists(71). HEK293T cells transfected with PSD-95 and CDKL5, and
treated with ionomycin, a calcium ionophore that raises intracellular calcium levels,
reduces the interaction between PSD-95 and CDKL5 five minutes after treatment.
Pretreatment with CMZ, calmidazolium, a CaM antagonist, does not prevent the
interaction between PSD-95 and CDKL5. Transfection with CDKL5 and PSD-95Y12E, a
mutated form that impairs Ca2+/CaM binding, also does not prevent the interaction.
Together this indicates that the Ca2+ interaction impairment is dependent on Ca2+/CaM
binding to PSD-95(71).
In summary, CDKL5 interacts with PSD-95 in a palmitoylation-dependent
manner. This interaction is dependent on the C-terminus of CDKL5 and C-terminal CDD
mutations may disrupt the PSD-95-CDKL5 interaction. Activity also perturbs the PSD-95CDKL5 interaction by calmodulin binding to PSD-95 in an NMDA-dependent manner.
Lack of the PSD-95-CDKL5 interaction likely results in altered spine density.
DIV7 mouse hippocampal neurons transfected with shRNA to knockdown CDKL5
showed more dendritic spines and spines with an altered, elongated morphology when
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immunostained at DIV15. CDKL5 also has reduced clustering with synaptic markers,
PSD95, VGluT1, and synaptophysin. Knockdown of CDKL5 in DIV15 neurons results in
reduced amplitude and frequency of mEPSCs. Altered spine morphology and reduced
clustering of CDKL5 with VGluT1 was also observed in vivo in P11 mice(35).
Endogenous CDKL5 colocalizes with both endogenous netrin-G-ligand 1 (NGL-1), a
postsynaptic adhesion molecule with roles in synaptic formation(72, 73), and transfected
NGL-1 in DIV15 hippocampal neurons. Immunoprecipitation assays from HEK293 cells
show CDKL5 binds to an intracellular domain of NGL-1(35). Co-immunoprecipitation
assays in P4 mouse synaptosomes also show CDKL5 and NGL-1 interact in vivo.
Knockdown of CDKL5 with shRNA in DIV14 cortical neurons causes a reduction in PSD95 interacting with immunoprecipitated NGL-1. HEK293T cells transfected with NGL-1
and a phosphodeficient mutant, S631A, were immunoprecipitated with Myc-CDKL5 and
subjected to an in vitro kinase assay. NGL-1S631A is not phosphorylated nor is it
immunoprecipitated. Immunoprecipitation of PSD-95 with Myc-NGL-1S631A, a
phosphodeficient form, from neurons co-transfected with Myc-NGL-1S631A and GFP-PSD95 reduces PSD-95 levels relative to wild-type NGL-1. DIV7 transfected hippocampal
neurons with the phosphodeficient form of NGL-1 and stained at DIV14 reduces the
number of dendritic protrusions and increases dendritic length, while the
phosphomimetic form of NGL-1 has a similar number of dendritic protrusions and
dendritic length compared to wild-type. The phosphodeficient NGL-1 also has reduced
clustering with PSD-95 compared to wild-type. Neurons transfected with shRNA for
CDKL5 have increased dendritic protrusions and increased dendritic length compared to
control. Co-transfection of shRNA CDKL5 and NGL-1S631E, a phosphomimetic form,
restores dendritic length but not the number of protrusions. In patient-derived iPSC
neurons, PSD-95 and VGluT1 puncta numbers are reduced but dendritic protrusion
length is increased relative to wild-type. These neurons also appeared to lack
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presynaptic terminals by the lack of adjacent localization of synaptophysin(35). Patientderived fibroblasts lacking CDKL5 and transfected with EGFP-NGL-1 have lower levels
of phosphorylated NGL-1 relative to control. Overexpressing CDKL5 in these fibroblasts
increases NGL-1 phosphorylation levels compared to the fibroblasts lacking CDKL5,
though levels are not restored to control levels(35).
In summary, loss of CDKL5 results in altered spine and morphology and synaptic
localization. CDKL5 interacts with PSD-95 through interactions with NGL-1, in a
phosphorylation-dependent manner at S631 of NGL-1.
Increasing concentrations of mind bomb 1 (Mib1), an E3 ubiquitin ligase that
marks proteins for proteasomal degradation, downregulates CDKL5 protein levels in
HEK293 cells. When co-transfected with a mutant form of Mib1 that inactivates its ligase
domain, CDKL5 levels are not downregulated. Through in vitro ubiquitination assays and
mass spectrometry, CDKL5 is ubiquitinated in the presence of Mib1, E1, E2, and Ub(33).
Mib1 reduces dendritic protrusions in DIV14 hippocampal neurons when transfected with
CDKL5, as compared to an increase when CDKL5 is expressed alone. This effect is not
replicated with neurons transfected with CDKL5 and the mutant form of Mib1 C985S, a
point mutation that renders the ligase domain inactive, indicating that active Mib1
opposes CDKL5 function. Spine morphology is also shifted to stubby/mushroom shape
when CDKL5 is co-expressed with Mib1(33). Together, this indicates that CDKL5 is
marked for degradation by Mib1 resulting in altered dendritic morphology.
Knockdown of CDKL5 with shRNA in DIV16-18 hippocampal neurons reduces
the protein levels of the GluA2 subunit of AMPAR. GluA2 mRNA levels are not reduced
when CDKL5 is knocked down, indicating that protein level reduction occurs posttranscriptionally. Knockdown of CDKL5 in mouse hippocampal neurons at DIV0 and
collected at DIV16-18 increases the ratio of phosphorylated GluA2 at S880 relative to
GluA2. Phosphorylation of GluA2 at this site controls the internalization of GluA2
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containing AMPARs that can undergo subsequent ubiquitination and degradation(7476). Levels of ubiquinated GluA2 are increased in neurons silenced for CDKL5 indicating
that GluA2 is marked for lysosomal degradation in the absence of CDKL5. Surface
GluA2 levels are also reduced when CDKL5 is knocked down in DIV18 hippocampal
neurons. Whole-cell clamping of DIV13 neurons silenced for CDKL5 at DIV10 clamped
at -70 and +50 mV show a reduction in amplitude at both voltages. +50 mV clamping
also had a reduction in decay tau. Collectively this indicates a reduction in GluA1/2
subunits, most specifically GluA2. Treatment of neurons silenced for CDKL5 with
tianeptine, an antidepressant, rescues GluA2 levels and the ratio of phosphorylated
S880P GluA2 relative to GluA2. Surface GluA2 levels are also rescued as are the
number of PSD-95 puncta(77). Together this indicates that CDKL5 regulates AMPAR
subunit composition of surface AMPARs.
Axonal Polarization
CDKL5 and Shootin1, a protein with functions in neuronal polarization(78, 79),
coimmunoprecipitate in vivo (P5-P7 mouse brains) and in vitro (HeLa cells). In vivo
mouse brain and in vitro neuronal expression of Shootin1 and CDKL5 overlap P4-14 and
DIV2-14. Shootin1 primarily localizes to the growth cone of axons where CDKL5 partially
colocalizes. Knockdown of Shootin1 or CDKL5 in hippocampal neurons using shRNA,
separately, reduces neuronal polarization in a similar manner. Loss of CDKL5 results in
an increase of neurons with multiple axons or no axon, while loss of Shootin1 results in
more neurons without an axon. Both loss of CDKL5 or Shootin1 result in aberrant neurite
growth, primarily due to decreased axon length. Similar to wild-type CDKL5
overexpression, hippocampal neurons transfected with a kinase dead form of CDKL5,
K42R, also results in reduced polarity and multiple axons, indicating that axon regulation
is dependent on CDKL5 kinase function. CDKL5 overexpression in neurons does not
result in multiple axons when Shootin1 is knocked down suggesting that CDKL5 acts
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upstream of Shootin1 in axonal regulation. Lastly, two-dimensional gel electrophoresis
reveals that CDKL5 directly or indirectly phosphorylates Shootin1(80). Thus, CDKL5 is a
regulator of axon polarization via its effects on Shootin1.
Degradation and Cell Death
Two isoforms of human CDKL5, CDKL5115 and CDKL5107 have similar cytosolic
and nuclear localization patterns in HeLa cells with and without treatment of leptomycinB(15). In HEK293T cells treated with cycloheximide and transfected with the CDKL5
isoforms, CDKL5115 isoform protein levels are degraded, while CDKL5107 and R781X
protein levels are not. Treatment with MG-132, a proteasome inhibitor, prevents
degradation of the CDKL5115 isoform and has no effect on the CDKL5107 or R781X,
indicating that the CDKL5115 isoform is degraded by the proteasome from a signal
between amino acids 904-1030(15). CDKL5 levels are degraded with prolonged
treatment of glutamate (3h). Treatment with MG-132 in combination with glutamate,
reduces degradation, while MG-132 alone, increased CDKL5 levels. Treatment with
EGTA, a Ca2+ chelator, and AP5, an NMDA antagonist, before prolonged glutamate
exposure reduces degradation, while bicuculline, a GABAAR antagonist, does not reduce
levels. Together this indicates that glutamate induced degradation is due to
extrasynaptic NMDARs. Treatment with hydrogen peroxide for 5h results in increased
CDKL5 degradation as does removal of neurotrophic factors for 24h, by growing in
media absent B27. An increase in degradation in response to these treatments likely
indicates a role in cell death signaling pathways(30).
Mouse DIV7 hippocampal neurons treated with KCl have increased CDKL5
levels as observed by Western blotting. P30-35 cortical slices treated with KCl also show
increased CDKL5 levels, indicating that CDKL5 levels are regulated by activity both in
vitro and in vivo. Hippocampal neurons pretreated with cycloheximide, a protein
synthesis blocker, before KCl prevents the increase in CDKL5 levels. DIV7 hippocampal
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neurons treated with KCl also have increased mRNA expression. Pretreatment of
neurons with actinomysin D, a transcription blocker, followed by KCl treatment does not
significantly change the mRNA levels. Collectively, this indicates the depolarizationdependent increase of CDKL5 is dependent on translation of existing mRNA levels.
CDKL5 levels increase in the dendrite but not the soma of DIV16 mouse cortical neurons
upon KCl treatment(34). Prolonged treatment of DIV7 neurons degrades CDKL5, as it
does in P30-35 cortical slices. DIV7 neurons treated with KCl for five minutes and placed
in recovery media for 3h also show a reduction in CDKL5 levels, while increasing the
recovery time to 24h results in CDKL5 levels similar to no treatment. DIV7 neurons
treated with KCl for 3h and MG132, a proteasome inhibitor, for 6h, results in a reduction
in CDKL5 proteins levels but closer to no treatment than to KCl alone. DIV7 hippocampal
neurons treated with KCl for 20 minutes display a protein size shift in CDKL5 that is
similar when treated with lambda phosphatase. This shift also occurs in N2a cells when
treated with lambda phosphatase, but not KCl, collectively indicating the shift is due to
dephosphorylation. Treatment of DIV7 hippocampal with KCl for 5 minutes and
recovered for 15 minutes results in a size shift similar to that with lambda phosphatase.
In cortical slices, the size shift becomes apparent at P11.5, though KCl treatment was
1h, while at P21 and P30, 5-minute KCl treatment is sufficient to induce the size shift.
DIV7 hippocampal neurons pretreated with EGTA followed by KCl treatment, do not
result in an increase of CDKL5 levels. Pretreatment with AP5, CNQX, and U0126 also
prevents CDKL5 level increase. However, AP5 and CNQX pretreatment of DIV3 neurons
results in CDKL5 protein levels increase. NMDA, forskolin, a PKA activator, and BDNF
treatment, separately, increases CDKL5 proteins levels in a manner similar to KCl
treatment. Extending the KCl treatment to 20 minutes and again pretreating DIV7
neurons with EGTA, AP5, CNQX, and U0126, results in a blockage of the size change
when treated with EGTA and AP5, indicating the size shift is dependent on calcium and
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NMDARs. Treatment with NMDA also results in the observed size change, while
prolonged treatment with BDNF and forskolin do not. Pretreatment with sodium
orthovanadate and deltamethrin does not prevent the size shift, while pretreatment with
calyculin does prevent the shift, indicating that dephosphorylation is dependent on either
PP1 or PP2A. Treatment with okadaic acid (OA), an inhibitor of PP2A, does not prevent
the dephosphorylation, indicating that it is dependent on PP1. To determine if the
degradation and dephosphorylation are linked, neurons were treated with prolonged KCl,
3h, and MG132, okadaic acid or both. As expected, MG132 results in CDKL5 levels
similar to control but the dephosphorylated form is prevalent. CDKL5 degradation is
partially blocked when treated with OA, as levels are not as reduced as KCl alone,
indicating that inhibition of dephosphorylation can reduce degradation. Furthermore, the
inhibition of PP1, before KCl treatment results in CDKL5 levels closest to control,
indicating that PP1 is necessary for degradation(34).
In summary, CDKL5 is dephosphorylated by PP1, protein phosphatase 1, in an
NMDAR-dependent manner. Prolonged activity causes dephosphorylation that may
signal CDKL5 to be degraded by the proteasome.
CDKL5 in glioma cell lines is increased for mRNA and protein compared to
normal specimens. U251, one of the glioma cell lines, transfected with CDKL5 shows
increased migration and invasion. Furthermore, CDKL5 transfection results in increased
protein expression of matrix metalloprotein 9 (MM9) and matrix metalloprotein 2 (MM2).
U251 cells have increased cell survival in an MTT assay when transfected with CDKL5
and conversely decreased cell survival when transfected with siCDKL5. U251 cells
transfected with CDKL5 also have a greater percentage of cells in S phase that was
reduced below control levels with siCDKL5. β-lapachone, a drug that stimulates
apoptosis in malignant cells, reduces cell viability and increases apoptosis in U251 cells.
When transfected with CDKL5, β-lap causes less cell death and cell viability is increased
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relative to β-lap treatment alone. Phosphorylated levels of PI3K, AKT, and GSK3β
relative to the non-phosphorylated forms are increased in U251 cells transfected with
CDKL5. The levels are decreased when transfected with siCDKL5. Mice injected with
U251 cells and CDKL5 in the flanks have increased levels of pAKT that are reduced with
cisplatin and XL147, a PI3K/AKT suppressor. Tumors are larger in these mice that was
ameliorated with cisplatin and XL147 treatment. IHC of these xenografts for Ki67, a
growth biomarker, show an increase in Ki67 concentration with CDKL5. Collectively,
these results show CDKL5 is involved in tumorigenesis through the PI3K/AKT
pathway(81).
Mouse Models for CDKL5 Deficiency Disorder
The predominant phenotypes in humans with CDD are associated with epilepsy,
autism, and learning and motor deficits. Associated deficits also include visual
impairment, gastrointestinal difficulties, and respiratory and sleep problems. A number of
rodent models have been generated and characterized in an effort to delineate a model
that mimics human CDD. Two types of murine models have been generated as part of
such efforts. One includes a null allele that can be generated by Cre-mediated
recombination and another expresses a human CDD mutant form that results in a
protein null phenotype.
Cdkl5 Cre-lox Models
Multiple floxed murine alleles of CDKL5 have been generated.
Zhou Model
Generation
The first Cre-lox mouse mimics a human splice site mutation and was generated
by inserting loxP sites flanking exon 7(exon 6 at the time of its publication). Excision of
exon 7 was completed by crossing chimeric offspring with C57BL/6 EIIa-Cre mice. The
EIIa promoter targets Cre recombinase expression in many mouse embryonic tissues.
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Excision of exon 7 results in a reading frame shift that truncates CDKL5 in the kinase
domain, likely representing loss-of-function(82). Loss of full-length CDKL5 was verified
by Western blotting.
Behavioral Characterization
Nine to twelve-week old CDKL5-/Y (CDKL5Fl/Y-EIIa-Cre) mice with exon 7
excised have impaired motor coordination but similar motor learning to the wild-type
mice from the rotarod assay. In a home-cage monitoring system, these mice display
hyperlocomotion. They also spend more time in the open arm and less time in the closed
arm of a zero-maze, indicating reduced anxiety. They exhibit impaired social activity in a
three-chamber social approach assay by spending less time with a stimulus mouse and
more time and sniffing with a non-stimulus object, relative to wild-type mice. In a paired
conspecific assay, the knockout CDKL5 mice interact less with a freely moving stimulus
mouse compared to wild-type mice. They have reduced nesting behavior. In a fear
conditioning assay, CDKL5-/Y mice have reduced freezing time compared to wild-type
mice when returning to the chamber and hearing the sound cue for a foot-shock. These
mice have normal EEG and lack spontaneous seizures. In response to auditory-evoked
event related potentials, CDKL5-/Y mice have deficits in the P1 and N2 peaks. They also
exhibit altered power and phase-locking factor at low-frequency oscillations, indicative of
disruptions in long-range circuit communications. CDKL5-/Y mice of 1-3 months(82) have
impairments in respiratory function(83).
CDKL5-/Y mice(82) show reduced social interaction and social recognition in a
three-chamber social test compared to wild-type. They also display communication
deficits via reduced ultrasonic vocalizations beginning at P6 and persisting through P8
and P10. Adult male mice also have reduced number and duration of female-induced
USVs compared to wild-type. Knockout male mice exhibit spontaneous digging behavior
that is amplified by injection with APO, a dopamine agonist, and persists longer than in
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wild-type mice. CDKL5-/Y mice also display hyperlocomotion, indicative of motor
impairments, in an open-field assay, and a reduced latency to fall in an accelerating
rotarod test. Mice do not display a significant change in thigmotaxis, indicating no altered
anxiety levels. CDKL5 knockout mice display more aggressive behavior in the residentintruder test than wild-type animals. CDKL5-/Y animals show an increased latency to
escape from a Barnes maze test, indicative of impaired spatial learning, though this
deficit did not persist on later probes days indicating the knockout mice do not have
impaired spatial memory(84).
Molecular Characterization
These mice show altered kinome profiles from Western blotting for numerous
motifs. Greatest fold changes are found in the AMPK, PKA, and AKT substrates. CDKL5/Y

mice display reduced levels of AKT at site S473 and mTOR at site S2448, indicating

that these pathways may be reduced activity with loss of CDKL5(82). AKT or PKB,
protein kinase B, is a serine/threonine kinase that regulates cell growth and proliferation.
In the context of CDKL5-/Y mouse brains, reduced AKT is likely associated with neuronal
development deficits. Through down-stream signaling cascades, AKT acts on mTOR.
Aberrations in this pathway are known to cause encephalopathies(85). Protein kinase A
(PKA) is involved in synaptic plasticity and AMP-activated protein kinase (AMPK) has
roles in cellular metabolism. CDKL5-/Y mice have reduced expression of opoid receptor
mu 1 (OPRM1) in the caudal and rostral striatum relative to wild-type mice. They have
altered forkhead box protein P2 (FoxP2) expression in the striatum, altered dopamine
levels in the medial prefrontal cortex and striatum, and increased TH, tyrosine
hydroxylase, protein levels in the medial prefrontal cortex and rostral striatum(84).
OPRM1 is associated with social and motor behaviors(86-89), while FoxP2 is required
for speech and language(90). Collectively, the presented pathways that are disrupted
likely contribute to the observed behavioral deficits in CDD.

24
Other Zhou Models
Generation
Conditional knockout mice were generated under the same the strategy and
crossed to Nex-Cre(91) mice to generate loss of CDKL5 in pyramidal neurons of the
dorsal telencephalon(92). Additionally, the exon 7 floxed mice were crossed with Dlx5-6Cre to knockout CDKL5 in forebrain inhibitory neurons(93). CDKL5 floxed mice(82)
crossed with Nex-Cre mice are null for CDKL5 in excitatory neurons in the forebrain,
most apparent in the cortex and hippocampus. Striatal CDKL5 protein levels are not
reduced, consistent with the expected recombination of the Nex-Cre line.
Behavioral Characterization
Nex-cKO mice show no significant change in locomotion, anxiety from an
elevated zero maze, motor learning or coordination from rotarod, olfaction, in grooming
or digging behaviors, or nesting behaviors relative to wild-type. They also show no social
interaction deficits from the three-chamber test, though they do display a slight increase
in locomotion. They also do not display differences in direct social interaction compared
to wild-type mice. Nex-cKO mice do display an increased number of entries and a
reduction in the percent of spontaneous alterations in the Y-maze test and number of
errors and preservations in the Barnes maze, collectively indicative of impaired
hippocampal function(92).
Conditional knockout mice for GABAergic neurons using the Dlx5-6 Cre driver
show sociability deficits in the three-chamber social test. They also display repetitive
grooming or digging behaviors. They have altered nesting behaviors and more errors
and preservations in a Barnes maze, indicative of impaired cognitive flexibility(93).
In summary, Nex-cKO mice have few altered behavioral phenotypes. The only observed
deficits indicate impaired hippocampal function. Conversely, deletion of CDKL5 in
inhibitory neurons under the Dlx5-6-Cre results in behavioral phenotypes, more
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overlapping with CDD, namely stereotypies, and social and hippocampal deficits.
Together, this may indicate that GABAergic neurons contribute to the pathology of the
disorder more so than glutamatergic neurons.
Molecular Characterization
CA1 pyramidal neurons of Nex-cKO mice show reduced dendritic branching in
apical and basal dendrites and reduced basal dendritic length. Spine density and volume
are not significantly altered in Nex-cKO CA1 pyramidal neurons, though they do trend
towards an increase. Whole-cell patch clamping of ex vivo hippocampal slices results in
a change in spike threshold, input resistance or in the input-output curve of Nex-cKO
slices compared to wild-type. Nex-cKO mice display increased mEPSC frequency in
CA1 neurons, though it was not significant. Additionally, Nex-cKO mice do not show a
significant increase in AMPA- or NMDA-induced EPSC amplitude, nor in NMDA/AMPA
ratio. Furthermore, the only difference between wild-type and Nex-cKO mice is a
reduction in interevent interval time and cumulative frequency for mEPSCs. This
difference is also present for mIPSCs. Nex-cKO CA1 pyramidal neurons also have
increased mIPSC frequency, though not to significance. However, the median decay
time and charge transfer rate are significantly increased. Together, this indicates that
Nex-cKO mice have altered excitatory and inhibitory synaptic activity. Stimulus
application to Schaffer collaterals and measuring the response by voltage sensitive dye
imaging in Nex-cKO results in enhanced depolarization in the stratum radiatum proximal
to the stimulus, indicating dendritic hyperexcitability. There is no difference in pairedpulse ratios from extracellular field recordings between wild-type and Nex-cKO mice,
indicating the dendritic hyperexcitability is likely postsynaptic. In the stratum oriens of
Nex-cKO mice proximal to the stimulus, depolarization and hyperpolarization are
enhanced, indicating an increase in perisomatic inhibition. In the stratum oriens of NexcKO mice distal to the stimulus, only hyperpolarization is enhanced indicating that
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excitation is constrained by enhanced inhibition. Collectively, this shows CA1 activation
is altered in a spatiotemporal manner(92).
Using voltage-sensitive dye imaging of the perforant path-dentate gyrus pathway
slices, Dlx-cKO mice show hyperexcitability in the granule cell and molecular cell layers
and hilus, while Nex-cKO mice showed hypoexcitability in the granule and molecular cell
layers. Using whole-cell patch clamp, Dlx-cKO mice have increased frequency in
mEPSCs in CA1 pyramidal neurons. mIPSCs are not altered. Additionally, Dlx-cKO mice
have increased protein levels of GluN1 and GluN2B(93).
In summary, Nex-cKO mice have reduced dendritic branching. Additionally, NexcKO mice have altered excitatory and inhibitory synaptic activity and are hyperexcitable.
This hyperexcitability likely occurs from the postsynaptic side. Within the stratum oriens
of Nex-cKO mice, perisomatic inhibition is prevalent and may restrict excitation. In DlxcKO mice, only excitatory synaptic activity is altered and may be due to increased
NMDA receptor expression.
Rescue Efforts
Treatment of Dlx-cKO mice with memantine, an NMDAR antagonist, ameliorated
excessive grooming behaviors and impaired social interaction(93).
Ciani Model
Generation
Another mouse model generated contains an upstream loxP site and
downstream FRT site of exon 4. These mice were crossed with C57BL/6J congenic
FLP-deleter mice and C57BL/6J congenic Cre-deleter mice under the Hprt promoter to
generate the Cdkl5 null allele(94). Western blotting shows CDKL5-/Y males and CDKL5-/females to be protein-null, while heterozygous females show reduced levels of full-length
protein.
Behavioral Characterization
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Nine to twelve-month old CDKL5-/Y(94) have sensorimotor deficits from impaired
prepulse inhibition. CDKL5-/Y have worse general health and are hypoactive at night. In
an openfield test, CDKL5-/Y are hyperactive. CDKL5-/Y also have reduced conditioned
fear memory(95).
Molecular Characterization
CDKL5-/Y mice have increased levels of phosphorylated PAK to total PAK and
increased cortical levels of rpS6 p240 relative to total rpS6, ribosomal protein S6. PAKs,
p21 activated kinases, are a group of serine/threonine kinases(96). Group I PAKs have
roles in regulating neuronal morphology and activity-dependent actin dynamics
associated with synaptic plasticity(97-99). Furthermore, overactivation of the Rac/PAK
pathway results in impairments in fear memory(100) and social learning(101). rpS6 is a
downstream target of mTOR and S6 kinase in a pathway for protein synthesis(102, 103).
CDKL5-/Y mice have reduced activity in brain mitochondrial respiratory chain (MRC)
complexes III, IV, and V, and when supplied with ascorbate/TMDP, the substrate for
complex IV, have a reduced ATP reduction rate compared to wild-type mice. Overall
brain mitochondria ATP levels are also reduced in CDKL5-/Y mice(95).
DIV4 mouse hippocampal neurons from CDKL5 knockout mice(94) show a
reduction in polarized neurons and axon length. DIV10 CDKL5 knockout hippocampal
neurons have a reduced number of intersections from Sholl analysis, indicating impaired
dendritic architecture. DIV15 CDKL5 knockout hippocampal neurons have reduced PSD95 puncta, and GluA2 levels in DIV14 CDKL5 knockout hippocampal neurons. COS7
cells silenced for CDKL5 with siRNA show a reduction in length and lifetime of CLIP170
comets, indicating CLIP170 has dissociated from microtubules. In DIV3 CDKL5 knockout
hippocampal neurons, CLIP170 levels show an increase relative to alpha-tubulin in the
growth cone. This mislocalization of CLIP170 in the absence of CDKL5 is due to intrinsic
properties of CLIP170, as overall CLIP170 levels were not altered when analyzed by
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Western blotting. Microtubule morphology is altered in CDKL5 knockout DIV3
hippocampal neurons as determined by alpha-tubulin staining(104). Collectively, these
results indicate CDKL5 interacts with CLIP170 to regulate microtubule dynamics and
morphology.
Rescue Efforts
Sensorimotor deficits observed in in CDKL5-/Y mice are rescued by treatment with
LP-211, a 5HT7R(serotonin receptor) agonist. LP-211 is not able to rescue any other
observed behavioral deficits. LP-211 increases cortical Rac1 activation in both wild-type
and CDKL5-/Y. Treatment with LP-211 increases the ratio of phosphorylated PAK to total
PAK in both genotypes, while the increase in levels of phosphorylated rpS6 are
abrogated with the treatment of LP-211. Reduced activity in MRC complexes III, IV, and
V is rescued by treatment with LP-211, as is the reduction in ATP production rate. LP211 treatment also rescues the reduction in overall brain mitochondria levels(95).
Pregnenolone or a synthetic derivative, drugs that promotes microtubule
dynamics by inducing the active formation of CLIP170(105), rescue the neuronal
polarization reduction and reduction in axon length. They also rescue and increase the
dendritic branching in Sholl analysis. Both drugs rescue the reduction in PSD-95 puncta
and GluA2 levels. Similar to pregnenolone, the synthetic form rescues the reduction in
length and lifetime of CLIP170. In neurons, CLIP170 localizes in growth cones and loss
of CDKL5 increases growth cone localization. Both forms of pregnenolone abrogated the
increase in localization of CLIP170 and the looping of microtubules.
CDKL5-/Y mice(94) show increased number of layer IV barrel cortex VGluT2
puncta in an enriched environment via whisker stimulation, though this increase is also
observed in wild-type animals. VGluT1 puncta were also increased in CDKL5-/Y animals
in an enriched environment, though not to statistical significance. CDKL5 knockout mice
have a reduced number of VGluT2/Homer and VGluT1/Homer appositions in layer IV
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barrel cortex in a standard environment that was rescued by an enriched environment,
indicative that thalamo-cortical connections can be rescued. No GABAergic connectivity
differences were observed by CDKL5 knockout mice in an enriched environment by no
change in VGAT puncta in layer IV barrel cortex. In a whisker nuisance task, CDKL5-/Y
mice showed altered sensory responses that were restored in an enriched environment.
CDKL5 knockout mice have reduced c-Fos expression in layer IV of the barrel cortex
that is restored with an enriched environment(106).
Tanaka Model
Generation
A third constitutive knockout mouse model(107) was generated by inserting loxP
sites flanking exon 2 and crossing Cdkl5flox/Y males to with CAG-Cre females resulting in
loss of Cdkl5 upon recombination(108). CDKL5 is completely knocked out in the brain of
CDKL5-/Y mice, confirmed by Western blotting and immunoperoxidase staining for
CDKL5 in whole brains. Heterozygous females showed reduced full-length protein
levels.
Behavioral Characterization
CDKL5-/Y mice(107) have reduced body temperature compared to wild-type mice.
There is no difference in weight, grip strength, pain sensitivity via hot plate test, or startle
response via prepulse inhibition. From gait analysis, some motor coordination
impairment in CDKL5-/Y mice is evident, though not in a one-day rotarod test. CDKL5-/Y
mice show increased anxiety from a light/dark transition test. CDKL5-/Y mice also show
delayed activity in a prolonged open field test, indicative of anxiety. They also spend less
time in the open arms of an elevated plus maze than wild-type. CDKL5-/Y mice show
reduced mobility in a Porsolt forced swim test and tail suspension test. CDKL5-/Y mice do
not display preference for an object or stranger mouse in a three-chamber social test,
similar to wild-type. However, in a one-chamber social test, CDKL5-/Y mice have altered
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social interactions compared to wild-type. CDKL5-/Y mice show altered fear conditioning
responses compared to wild-type. Similar to other CDKL5-/Y mouse models, the
generated model has impaired acquisition and retention of spatial memory from the
Barnes water maze(109).
Molecular Characterization
CDKL5-/Y mice have altered basal and apical dendritic arborization and spine
morphology. Four week and 13-15-week old CDKL5-/Y mice exhibit increased seizure
susceptibility to NMDA treatment but do not vary from wild-type when treated with kainic
acid. Schaffer collateral-CA1 synapses in acute hippocampal slices show increased
potentiation and LTP in CDKL5-/Y mice. Treatment of the slices with D-APV, an NMDA
antagonist, resulted in no differences in potentiation, indicating that the differences are
NMDA-dependent. Reinforcing this concept is the NMDA/AMPA ratio increase observed
in CDKL5 knockout mice. The decay time was also larger in CDKL5 knockout mice. In
the hippocampus of adult CDKL5-/Y mice, GluN2B protein levels are increased in the
PSD-1T(postsynaptic density fraction). In the PSD-1T fraction, SAP102, a GluN2B
trafficker, is increased in CDKL5-/Y mice. CDKL5-/Y mice also display this increase in
GluN2B and SAP102 on the immunohistological level. Additionally, GluN1 also shows an
increase though not to statistical significance. The overaccumulation of GluN2B and
SAP102 is not activity related as no differences between wild-type and knockout were
observed in C2’/C2 ratio or ubiquitin conjugation(107).
Rescue Efforts
Treatment of CDKL5-/Y mice with ifenprodil, a GluN2B antagonist, resulted in
abrogation of NMDA-induced seizures(107).
Arikkath Model
Generation
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An additional knockout mouse was generated by inserting loxP sites into intron 3
& 4 that upon Cre-mediated deletion resulted in excision of exon 4. When crossed to
CaMKIIα-Cre or GAD-2-IRES-Cre, the resulting mice have loss of CDKL5 in forebrain
pyramidal neurons or GAD2-positive neurons (GABAergic), respectively(110). Fulllength CDKL5 levels are reduced in the cortex of CDKL5 Fl/Y-CaMKIIα-Cre mice, an
area of abundant pyramidal neurons. Full-length CDKL5 levels are also reduced in the
striatum of CDKL5 Fl/Y-GAD-2-IRES-Cre mice, an area with a higher percentage of
GABAergic neurons.
Behavioral Characterization
No behavioral studies have been performed on these mice.
Molecular Characterization
These studies are described in Chapter 1.
Cdkl5 Knock-in Model
Zhou Model
Generation
A knock-in mouse model was generated with a single nucleotide change of C to
T resulting in a nonsense mutation at R59(R59X)(93). This model abolishes full-length
CDKL5 expression as examined by Western blot analysis.
Behavioral Characterization
R59X mice display excessive grooming and impaired social interaction that is
ameliorated with memantine treatment(93). CDKL5 R59X mice displaye thigmotaxis and
hyperlocomotion in an open field test. CDKL5 R59X mice have impaired motor
coordination and motor learning in a rotarod assay. They display increased hindlimb
clasping and reduced social interaction in both a three-chamber and direct social
interaction test. R59X also display impaired working memory from Y-maze and fear
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responses from foot shock. Following injection with PTZ, pentylenetetrazol, to induce
seizure, R59X mice showed a reduction in onset time(111).
Molecular Characterization
Around P30, R59X mice show a reduction in GluA2 levels in the hippocampus
that persists throughout adulthood. This reduction is not observed in the cortex. NMDA
receptor subunits GluN2A and GluN2B are not altered in R59X in either the
hippocampus or cortex, though R59X CDKL5 mice have increased levels of GluN2B in
the postsynaptic density. GluA2 puncta containing synapses in the CA1 of R59X mice
are reduced compared to wild-type, indicating an increase in GluA2-lacking AMPARs in
CA1 hippocampus. Whole-cell patch-clamp recordings from CA1 acute hippocampal
slices showed altered eEPSCs in R59X mice.
Rescue Efforts
Treatment with two GluA2-lacking AMPAR antagonist, IEM-1460 and NASPM,
decreased current, indicating that GluA2-lacking AMPARs contribute to AMPA current in
R59X mice. R59X mice have elevated early-phase LTP from extracellular ex vivo
hippocampal slices. Treatment of R59X mice with IEM-1460 rescues social, memory,
and fear behaviors in addition to seizure amelioration. Human patients show a trend
towards a reduction in GluA2 levels in the hippocampus(111).
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CHAPTER 1: NEURON-TYPE SPECIFIC LOSS OF CDKL5 LEADS TO
ALTERATIONS IN MTOR SIGNALING AND SYNAPTIC MARKERS
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Introduction
CDKL5 Deficiency Disorder is a devastating neurodevelopmental disorder
associated with neurodevelopmental phenotypes, autism(112), intellectual disability, and
epilepsy(113, 114). CDKL5 encodes CDKL5, a protein with homology to the serinethreonine kinases. Structurally, the protein has a kinase domain and putative nuclear
localization and nuclear export signals. The functional roles of CDKL5 are incompletely
characterized, but include roles in regulation of synaptic density, architecture and
stability(34, 35, 39), postsynaptic localization of NMDA receptors(107), surface
expression of AMPA receptors(77), neuronal polarization(80), microtubule dynamics(69),
RNA splicing(31), synaptic connectivity in the cortex(115), dendritic spine stability(116),
and dendritic architecture(117). Loss of CDKL5 in mouse models leads to phenotypes
associated with CDKL5 disorder, including autistic phenotypes(82), memory
impairment(92), increased seizure susceptibility(107), and sleep apnea(118). Thus,
CDKL5 is a critical regulator of neural circuit function and disruption of these functional
roles in CDKL5 disorder likely contributes to neural circuit deficits and behavioral
outcomes associated with the disorder.
Neurodevelopmental disorders with phenotypes similar to those observed in
CDKL5 disorder vary in their origin and etiology and several genetic mouse models
recapitulate core features of these disorders(119). However, aberrations in mechanistic
target of rapamycin (mTOR) signaling pathways(120-122) and synaptic density, function,
and architecture are commonly observed in a variety of disorders associated with similar
phenotypes(123, 124).
To begin to address the functional roles of CDKL5 in vivo, we generated and
validated a mouse model bearing a floxed allele of CDKL5. We also generated a rabbit
polyclonal antibody to CDKL5 and validated this and two commercial antibodies on
tissue from Cre-mediated recombination. We examined the brain region distribution of
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CDKL5. Our data indicate that CDKL5 is well expressed in the cortex, hippocampus, and
striatum, with little expression in the olfactory bulb and cerebellum. Further, CDKL5 is
localized in synaptosomes and nuclei and developmentally regulated in the
hippocampus. By taking advantage of Cre-mediated recombination, we examined the
effects of loss of CDKL5 in excitatory neurons (CaMKIIα-positive) or inhibitory (GAD65positive) neurons on components of the mTOR signaling pathway and loss of CDKL5 in
excitatory (CaMKIIα-positive) or inhibitory (GAD65-positive) neurons on excitatory
synaptic markers. These data support a model in which loss of CDKL5 alters mTOR
signaling and synaptic compositions in a neuron-type specific manner and suggest that
CDKL5 may have distinct functional roles in excitatory and inhibitory neurons.
Experimental Procedures
CDKL5 Conditional Knockout Mouse
The mouse CDKL5 gene consists of 22 exons(14) of which the fourth exon was
targeted for creating a conditional knockout allele. The targeting construct was
commercially synthesized that contained a left and right homology arms of 7.3 and
6 kilobases respectively along with the upstream LoxP site in intron 3, and a Frt-Neo-FrtLoxP cassette in intron 4. If a truncated protein is expressed from the upstream exons, it
will produce only about 33 amino acid polypeptides, along with another 29 amino acids
originating from frameshifted reading of the exon 6. Upon Cre-mediated deletion of the
exon 4, the transcript will undergo nonsense-mediated decay due to frameshift in the
protein coding sequence of the downstream exons. The targeting construct was
linearized and electroporated into C57BL6/J-derived ES cells(125); the positive clones
were screened by long range PCRs and confirmed by southern blotting. The ES cell
clones were injected into Albino C57BL6/J (https://www.jax.org/strain/000058) strainderived blastocysts, to generate chimeras, at the mouse genome engineering core
facility, UNMC. A genotyping PCR assay was developed for detecting the conditional
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knockout allele. The primer pairs were CDKL5 Flox F
TGCTCTTGGAGTATGTTGATTGAC and CDKL5 Flox R
ACTTGGAATCATAATACTGTATACCTTG. The expected amplicons sizes are 204 and
267 bp, for wild-type and conditional KO alleles respectively. The floxed mice were bred
to Cre mice to generate neuron-specific conditional knockout allele for CDKL5. The loss
of CDKL5 protein expression, in the target tissue, was confirmed by Western blotting.
Animals
All animal experiments were approved by Institutional Animal Care and Use
Committee of the University of Nebraska Medical Center. Mice were housed with 12/12h dark/light cycle with free access to food and water. The heterozygous CDKL5fl females
were mated with homozygous CaMKIIα-Cre (the Jackson Laboratory, Stock No. 005359)
or Gad2-IRES-Cre (the Jackson Laboratory, Stock No. 019022) male. Three offspring
from homozygous CDKL5fl female and heterozygous Gad2-IRES-Cre male were also
included and no significant difference were observed. Only male mice were included in
this study.
Immunoblotting
Mice were anesthetized by isoflurane and brain tissues from the cortex and
striatum were dissected out in cold 1× PBS on ice. Tissues were quick-frozen on dry ice
and stored at − 80 °C. For tissue lysate preparation, cold lysis buffer, including 50 mM
Tris pH 7.4, 107 mM NaCl, 1% Triton X-100, 0.1% SDS, 1:100 protease inhibitor (Sigma,
P8340), 1:100 phosphatase inhibitor (Sigma, P0044), 5 mM EDTA, and 5 mM EGTA,
was added to the samples before thawing, to minimize nonspecific cleavage by
protease. Tissues were then homogenized by sonication (22–25% amplitude, 2-s
sonication for 3–8 times according to the size of the tissue, with at least 60-s interval
between each sonication) on ice and centrifuged 15,000 rpm for 5 min at 4 °C.
Supernatants were loaded on 7.5% or 10% hand-casted SDS-PAGE, with 15–50 μg of
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protein per well. The dilutions of antibodies for immunoblot are as follows: 1:100 NR2B
(NeuroMab, clone N59/36, 73-101), 1:100 PSD-95 (NeuroMab, clone K28/43, 73-028),
1:1000 Arc (Santa Cruz Biotechnology C-7, sc-17839), 1:8000 VGLUT1 (Millipore,
AB5905), 1:5000 N-cadherin (BD Bioscience, 610920), 1:2000 CaMKIIα (Millipore, clone
6G9, 05-532), 1:1000 mTOR (Cell Signaling Technology, 2983), 1:1000 pmTOR(S2448) (Cell Signaling Technology, 5536), 1:1000 p-mTOR(S2481) (Cell
Signaling Technology, 2974), 1:1000 p-TSC2(S1387) (Cell Signaling Technology, 5584),
1:1000 p-p70S6K(T389) (Cell Signaling Technology, 9234), 1:1000 p70S6K (Cell
Signaling Technology, 9202), 1:1000 TSC2 (Cell Signaling Technology, 4308), 1:1000
Rag C (Cell Signaling Technology, 5466), 1:1000 Rag B (Cell Signaling Technology,
8150), 1:1000 Rag A (Cell Signaling Technology, 4357), 1:1000 p-TSC2(S939) (Cell
Signaling Technology, 3615), 1:10000 p62 (Abcam, ab109012), 1:200 β-tubulin (DHSB,
E-7), 1:200 actin (DHSB, JLA20), 1:16000 HRP-conjugated anti-rabbit IgG (Jackson
ImmunoResearch 711-035-152), 1:16000 HRP-conjugated anti-mouse IgG (Jackson
ImmunoResearch 711-035-151), 1:6000 HRP-conjugated anti-guinea pig IgG
(Invitrogen, 614620). The CDKL5 antibody Rabbit 6680 was generated using a peptide
spanning as indicated in Figure 1 using a commercial vendor.
Quantitation of Westerns
Blots were detected by SuperSignal West Dura Chemiluminescent Substrate
(Thermo, 34075), imaged by FluorChem HD2 (Cell Biosciences), and quantified on
AlphaView (ProteinSimple) or ImageJ. After background subtraction, band intensity was
normalized to housekeeping protein (β-tubulin or actin accordingly). Individual values
were then normalized to the geometric mean of the litter so that unpaired statistical tests
can be performed. For every western blot band that was quantitated, we ensured that
the signal was not saturated using tools available with the AlphaView software.
Primary Neuron Culture from E18 Rats
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As previously described(126).
Nuclear Preparation
Primary rat neurons were washed with 1× PBS. Culture dishes were incubated
on a shaker with 600 μL per 100-mm dish of 1× Buffer A (0.5 M HEPES, 2 M KCl, 0.5 M
EDTA, water), 4% NP-40, and 1% protease and phosphatase inhibitors for 15 min at
4 °C on ice. Cells were scraped using a disposable cell scraper. The homogenate was
centrifuged at 15,000×g for 3 min at 4 °C. Tubes were placed on ice and the supernatant
was collected as the cytosolic fraction. Three washes of 250 μL of 1× Buffer A (NP-40)
were performed with centrifugation at 15,000×g for 3 min at 4 °C between washes. The
pellet was resuspended in 1× Buffer B (0.5 M HEPES, 5 M NaCL, 0.5 M EDTA, 40%
glycerol, water) and 1% protease and phosphatase inhibitors and vortexed for 10 s. The
homogenate was placed on ice on a shaker in a cold room for 2 h. Tubes were
centrifuged at 15,000×g for 5 min at 4 °C and the supernatant was collected as the
nuclear soluble fraction. Three washes of 100 μL of 1× Buffer B were performed with
centrifugation at 15,000×g for 3 min at 4 °C between washes. The final pellet was
suspended in RIPA buffer and sonicated to produce lysates for Western blot analysis.
Synaptosome Preparation
Dissected brain tissue (hippocamus ~ 20 mg; cortex ~ 40 mg from mouse P21
brain) was homogenized in 10 volumes of the Syn-PER Reagent (ThermoScientific No.
87785, both protein phosphatase inhibitors and protease inhibitors included) using a 2mL Dounce tissue grinder with 13 up-and-down even strokes (all procedures on ice).
The homogenate was centrifuged at 1200×g for 10 min to pellet synaptoromes. To
further remove residual cell debris, the pellet was resuspended in Syn-PER Reagent and
centrifuged again (1200×g, 10 min). For Western blot, the pellets, containing
synaptosomes, were suspended in the RIPA buffer. When needed, to the supernatant
(after the initial 1200×g centrifugation), 5× RIPA buffer was added and briefly sonicated
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to produce lysates for Western blot analysis (synptosome-minus fraction). To get cytosol
fraction, the supernatant (after the initial 1200×g centrifugation) was centrifuged for
20 min at 15,000×g. When needed, the remaining pellet (enriched for big organelles and
membrane) was resuspended in RIPA buffer for Western Blot analysis.
Statistics
All the statistical tests were performed on Prism 7 (GraphPad). Normality of
every group was first tested by D’Agostino and Pearson normality test and statistical
tests were performed accordingly. Groups with too few data points for the normality test
were treated as normally distributed.
Results
Generation and Validation of Floxed CDKL5 Mice and CDKL5 Antibodies
We generated a conditional murine allele (Fig. 1a) using standard techniques by
generating a floxed allele of CDKL5 flanking exon 4. Cre-mediated recombination is
likely to generate a null allele (see the “Methods” section). We generated a rabbit
polyclonal peptide antibody to the C-terminal region of the mouse CDKL5 (Fig. 1b),
including amino acids 636-758 (Fig. 1c). In addition to this antibody, two commercial
antibodies to CDKL5 are also available (Sigma—aa 636-758 and Abcam—aa750-850).
We generated mouse models in which CDKL5 is deleted from the cortical excitatory
neurons by crossing the CDKL5 floxed allele into the CaMIIα-Cre line or from GABAergic
neurons by crossing the CDKL5 floxed allele into the Gad2-IRES-Cre line. We examined
the expression of CDKL5 in the CDKL5 Fl/Y or CDKL5 Fl/Y-CaMKIIα-Cre cortex by
Western blot analysis with all the three antibodies. The levels of CDKL5 detected by all
three antibodies, Rbt 6680 (Fig. 1d, h), Abcam (Fig. 1e, i), and Sigma (Fig. 1f, j), were
significantly reduced in the CDKL5 Fl/Y Cre mice in comparison to control. Rbt 6680 also
reacts with an additional higher molecular weight nonspecific band. We similarly
examined the expression of CDKL5 in the striatum from the CDKL5 Fl/Y-Gad2-IRES-Cre
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mice. The striatum is predominantly composed of GABAergic neurons. Similar to the
results observed with the CDKL5 Fl/Y-CaMKIIα-cre mice, the levels of CDKL5 in the
CDKL5 Fl/Y-Gad2-IRES-Cre striatum were significantly reduced (Fig. 1g, k). These
results indicate that (1) Cre-mediated recombination of the floxed allele of CDKL5 results
in loss of CDKL5 protein and (2) the three antibodies are specific to CDKL5.
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Figure 1. Generation and validation of CDKL5 mouse model and CDKL5
antibodies. a Schematic of targeted locus and locus after Cre-mediated
recombination. b Schematic of CDKL5 with different known domains indicated—
sequence based on human CDKL5. c Schematic of CDKL5 with location of three
antibody epitopes. The Sigma and Abcam are commercial antibodies and Rbt 6680 is a
custom polyclonal peptide antibody. d Western blots of cortical lysates from CDKL5 Fl/Y
+/− CaMKIIα-Cre with anti-CDKL5—Rbt6680. E. Western blots of cortical lysates from
CDKL5 Fl/Y +/− CaMKIIα-Cre with anti-CDKL5—Abcam. f Western blots of cortical
lysates from CDKL5 Fl/Y +/− CaMKIIα-Cre with anti CDKL5—Sigma. g Western blots of
striatal lysates from CDKL5 Fl/Y +/− Gad2-IRES-Cre with anti CDKL5—Rbt 6680 (d–
g data N = 3 for each genotype). h Levels of CDKL5 relative to β-tubulin in cortical
lysates from CDKL5 Fl/Y +/− CaMKIIα-Cre with anti CDKL5—Rbt 6680. i Levels of
CDKL5 relative to β-tubulin in cortical lysates from CDKL5 Fl/Y +/− CaMKIIα-Cre with
anti CDKL5—Abcam. j Levels of CDKL5 relative to β-tubulin in cortical lysates from
CDKL5 Fl/Y +/− CaMKIIα-Cre with anti CDKL5—Sigma. k Levels of CDKL5 relative to βtubulin in striatal lysates from CDKL5 Fl/Y +/− Gad2-IRES-Cre with anti CDKL5—Rbt
6680 (h–k data presented ± SEM, *P < 0.05, **P < 0.005, ***P < 0.0005, Student’s t test
assuming equal variances).
Expression Pattern of CDKL5
We examined the expression of CDKL5 in different regions of the mouse brain
using Western blot analysis (Fig. 2a, b). CDKL5 is predominantly expressed in the
cortex, striatum, and hippocampus with little expression in the cerebellum and olfactory
bulb. To examine the subcellular distribution of CDKL5, we examined the expression of
CDKL5 in synaptosomal preparations from the mouse cortex. CDKL5 is well expressed
in synaptosomal fractions as indicated by co-enrichment with PSD-95, an excitatory
postsynaptic marker (Fig. 2c). This is consistent with literature. We also examined the
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subcellular distribution of CDKL5 in the nucleus by Western blot analysis of cytosolic and
nuclear fractions from cultured primary rat neurons. Nuclear fractions are enriched in
histone H3. CDKL5 is localized in nuclear fractions (Fig. 2d). Taken together, these
results suggest that CDKL5 is predominantly expressed in the cortex, hippocampus, and
striatum and localized to synaptosomes and nuclei.

Figure 2. Regional and temporal expression patterns for CDKL5. a Western blots for
CDKL5 (Sigma) in different regions of the mouse brain as indicated (P28,
male, N = 3). b Levels of CDKL5 relative to β-tubulin in different regions of the mouse
brain (P28, male, N = 3) (data ± SEM). c Western blot for CDKL5 (Sigma) and PSD-95
(excitatory synaptic marker) in synaptosomal preparations from mouse cortex
(adult, N = 3). d Western blot for CDKL5 (Sigma), histone H3, and Na+/K+-ATPase in
cytosol and nuclear preparations from primary rat neurons.
Developmental Expression of CDKL5
We examined the expression pattern of CDKL5 in the hippocampus across
development (Fig. 3a). CDKL5 was well expressed at all stages during development and
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in the adult. Our data suggest that there may be trends towards expression peaks
around P21–P28; however, these did not reach statistical significance (Fig. 3b). We
compared the molecular weights of the mouse CDKL5 from hippocampal tissue (P21)
and rat CDKL5 from in vitro primary cultures by Western blot analysis with Rbt 6680
(Fig. 3c). Unlike the mouse lysates, Rbt 6680 only detects a single CDKL5 specific band
in rat lysates. We also examined developmental expression of CDKL5 in the rat
hippocampus (Fig. 3d, e). Similar to the mouse hippocampus, CDKL5 is well expressed
at time points coincident with neural circuit formation and refinement. We further
examined the expression of CDKL5 in primary rat neurons at DIV 7, 14, and 21 (Fig. 3f,
g). Similar to the in vivo data, we observe expression of CDKL5 in primary neurons at
time points coincident with synapse formation and maturity. Taken together, these
results indicate that the expression of CDKL5 is developmentally regulated in the
hippocampus, both in vivo and in vitro.

Figure 3. Developmental expression of CDKL5 in rat and mouse
hippocampus. a Western blot for CDKL5 in hippocampal lysates at indicated time
points (N = 3). b Levels of CDKL5 relative to β-tubulin at indicated time points in the
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mouse hippocampus. Levels were normalized to percentage of adult levels. c Western
blot for CDKL5 (Rbt 6680) in P21 mouse hippocampal lysate and rat primary neuron
lysates. d Western blot for CDKL5 (Rbt 6680) in hippocampal lysates from P7 to adult
rat tissue (N = 3). e Levels of CDKL5 relative to β-tubulin at P7 to adult in the rat
hippocampus. f Western blot for CDKL5 (Rbt 6680) in hippocampal lysates from primary
rat neurons at DIV 7, 14, and 21 (N = 3). g Levels of CDKL5 relative to β-tubulin in
hippocampal lysates from primary rat neurons at DIV 7, 14, and 21.
Expression of Components of the mTOR Signaling Pathway with Loss of CDKL5
in Excitatory Neurons of the Mouse Cortex
The mechanistic target of rapamycin (mTOR) pathway coordinates cellular
signaling and metabolic pathways with environmental inputs(127). Alterations in
components of the mTOR signaling pathway have been observed in a variety of models
of neurodevelopmental disorders associated with phenotypes common to CDKL5
disorder(120, 128, 129). We examined the levels of components of the mTOR pathway
by Western blot analyses in cortical lysates from CDKL5 Fl/Y CaMKIIα-cre mice. The
levels of p62, mTOR, pmTORS2448, pmTORS2481, pTSC2S1387, pTSC2S939, Rag A,
and Rag B in the CDKL5 Fl/Y CaMKIIα-Cre lysates were not significantly altered in
comparison to control mice. The levels of TSC2 and Rag C showed trends towards a
decrease; however, these did not reach significance. Interestingly, the levels of
pp70S6K1T389 were significantly reduced in lysates from the CDKL5 Fl/Y CaMKIIα-Cre
mice in comparison to control lysates (Fig. 4a, b). These alterations were accompanied
by similar change in the level of p70S6K1, suggesting that the reduction in the levels of
the phosphorylated form is likely a secondary consequence of reduction of total levels of
p70S6K1 (Fig. 4c). These data indicate that selective loss of CDKL5 in excitatory
neurons of the cortex leads to deficits in expression of components of the mTOR
signaling pathway.
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Figure 4. Alterations in levels of components of mTOR signaling pathway with
loss of CDKL5 in cortical excitatory (CaMKIIα-positive) neurons. a Western blots for
components of the mTOR signaling pathway as indicated in cortical lysates from CDKL5
Fl/Y +/− CaMKIIα-Cre tissue. b Levels of components of the mTOR signaling pathway
relative to β-tubulin as indicated in cortical lysates from CDKL5 Fl/Y +/− CaMKIIα-Cre
tissue. c Ratio of p70S6K1 to p70S6K1T389 from indicated genotypes (data presented ±
SEM, *P < 0.05, **P < 0.005, ***P < 0.0005, Student’s t test with Welch correction. N = 3
for each genotype; age 8–11 weeks).
Expression of Components of the mTOR Signaling Pathway with Loss of CDKL5
in Inhibitory Neurons of the Mouse Cortex
CDKL5 is well expressed in the striatum (Fig. 2a, b). It has previously been
demonstrated that loss of CDKL5 in a mouse model enhances the connectivity between
the parvalbumin-positive neurons and pyramidal neurons in the V1 cortex as examined
by VGLUT1 immunostaining(115). Further, Dlx5/6-Cre-mediated deletion of CDKL5 in a
floxed mouse model decreases home-cage activity in a sex-specific manner. These data
suggest that GABAergic neurons likely contribute to the pathology of the CDKL5
disorder and loss of CDKL5 in GABAergic neurons may lead to signaling alterations
relevant to the disorder. To examine levels of mTOR pathway components in the
absence of CDKL5 in GABAergic neurons, we generated mice bearing the CDKL5 Fl/Y
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and Gad2-IRES-Cre alleles(130). Since the striatum is heavily enriched in GABAergic
neurons, we examined the levels of mTOR signaling pathway markers in striatal lysates
from control and mutant littermates by Western blot analysis. The levels of p62, mTOR,
pmTOR S2481, TSC2, pTSC2S1387, pTSC2S939, Rag A, and Rag B in the CDKL5 Fl/Y
Gad2-IRES-Cre lysates were not significantly altered in comparison to control mice. The
levels of pmTORS2448 showed a trend towards an increase; however, these did not
reach significance. In contrast to the effects of loss of CDKL5 in excitatory neurons, the
levels of p70S6K1 trended towards an increase in the mutants. However, these did not
reach significance. In further contrast to the effects of loss of CDKL5 in excitatory
neurons, the levels of Rag C were significantly increased in the mutant animals (Fig. 5a,
b). These data indicate that selective loss of CDKL5 in inhibitory neurons of the striatum
leads to deficits in expression of components of the mTOR signaling pathway. However,
these alterations do not mirror the effects observed in excitatory neurons, suggesting
that loss of CDKL5 in excitatory and inhibitory neurons differentially affects signaling
mediated by the mTOR pathway.

Figure 5. Alterations in levels of components of mTOR signaling pathway with
loss of CDKL5 in striatal inhibitory (GAD65-positive) neurons. a Western blots for
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components of the mTOR signaling pathway as indicated in cortical lysates from CDKL5
Fl/Y +/− Gad2-IRES-Cre tissue. b Levels of components of the mTOR signaling pathway
relative to β-tubulin as indicated in cortical lysates from CDKL5 Fl/Y +/− Gad2-IRES-Cre
tissue (data presented ± SEM, *P < 0.05, **P < 0.005, ***P < 0.0005, Student’s t test with
Welch correction; N = 5 for each genotype; age 4–20 weeks).
Expression of Excitatory Synaptic Markers with Loss of CDKL5 in Excitatory
Neurons of the Mouse Cortex
CDKL5 is localized at synapses(35) (Fig. 2) and loss of CDKL5 perturbs
excitatory synapse density and function. Synaptic alterations are commonly observed in
several models of neurodevelopmental disorders associated with autism, intellectual
disability, and related deficits. Further, loss of CDKL5 in excitatory neurons via Emx-Cremediated deletion(94) recapitulates some behavioral features of the disorder, particularly
increased hindlimb clasping, suggesting that loss of CDKL5 in excitatory neurons may
perturb synaptic compositions. We examined levels of some excitatory synapse markers
in cortical lysates from CDKL5 Fl/Y +/− CaMKIIα-Cre mice (Fig. 6). The levels of NR2B
and VGLUT1 were not significantly altered with loss of CDKL5 in cortical excitatory
neurons. Interestingly, the levels of PSD-95 showed a significant increase in the
absence of CDKL5. We also examined the levels of Arc, a protein encoded by
immediate early gene Arc, and CaMKIIα, an excitatory neuronal marker, in these lysates.
The levels of these markers were not significantly altered in the absence of CDKL5.
Taken together, these data indicate that loss of CDKL5 in excitatory neurons in the
cortex alters the levels of some excitatory synaptic markers.
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Figure 6. Alterations in excitatory synaptic composition with loss of CDKL5 in
cortical excitatory (CaMKIIα-positive) neurons. a Western blots for synaptic markers
as indicated in cortical lysates from CDKL5 Fl/Y +/− CaMKIIα-Cre tissue. b Levels of
synaptic markers as indicated relative to actin as indicated in cortical lysates from
CDKL5 Fl/Y +/− CaMKIIα-Cre tissue (data presented ± SEM, *P < 0.05, **P < 0.005,
***P < 0.0005, Student’s t test with Welch correction; N = 4 for each genotype; age 11–
56 weeks)
Expression of Excitatory Synaptic Markers with Loss of CDKL5 in GABAergic
Neurons of the Mouse Striatum
We examined the effects of loss of CDKL5 in GABAergic neurons on synaptic
markers by Western blot analysis in striatal lysates from control and mutant littermates
(Fig. 7). The levels of NR2B, PSD-95, and VGGLUT1 were not altered with loss of
CDKL5. In addition, unlike the effects observed with loss of CDKL5 in excitatory
neurons, we did not observe any strong trends for alterations in levels of PSD-95 with
loss of CDKL5 in GABAergic neurons. In addition, the levels of Arc, an activity-regulated
gene, and CaMKIIα, a marker for excitatory glutamatergic neurons, were not significantly
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altered. Taken together, these data suggest that loss of CDKL5 in GABAergic neurons of
the striatum does not significantly alter levels of excitatory synaptic markers.

Figure 7. Synaptic composition is maintained with loss of CDKL5 in striatal
inhibitory (GAD65-positive) neurons. a Western blots for synaptic markers as
indicated in striatal lysates from CDKL5 Fl/Y +/− Gad2-IRES-Cre tissue. b Levels of
synaptic markers as indicated relative to actin as indicated in striatal lysates from CDKL5
Fl/Y +/− Gad2-IRES-Cre tissue (data presented ± SEM, *P < 0.05, **P < 0.005,
***P < 0.0005, Student’s t test with Welch correction; N = 6 for control and N = 8 for
CDKL5 Fl Y/− Gad2-IRES-Cre; age 4–25 weeks)
Discussion
CDKL5 disorder is a disorder with neurodevelopmental phenotypes, including
motor deficits, intellectual disability, autism, and epilepsy. In this study, we have made
several significant observations relating to the biology of CDKL5, encoded by CDKL5,
that are likely relevant to dissecting the molecular pathology of the disorder.

50
Our data indicate that CDKL5, encoded by CDKL5, is expressed predominantly
in the cortex, hippocampus, and striatum with lower expression in the cerebellum and
olfactory bulb. These regions are associated with higher order functions including
thought, action, learning, memory, and voluntary movement. The expression pattern of
CDKL5 in these regions and the phenotypes associated with CDKL5 disorder suggest
that CDKL5 is a critical regulator of neural circuits predominantly in these brain regions.
Previous studies indicate that loss of CDKL5 in the cerebellum(131) leads to impaired
motor coordination and gait, accompanied by reduction of GAD67 in the molecular layer
with no alterations in the levels of VGLUT1 and reduced levels of BDNF mRNA. These
results suggest that while the expression levels of CDKL5 in the cerebellum are low,
they are functionally significant and that functional roles of CDKL5 in regions other than
the hippocampus, cortex, and striatum may also be critical to the pathology of CDKL5
disorder. Further, the developmental expression of CDKL5 coincides with the periods of
neural circuit formation and refinement, consistent with a role for CDKL5 in neural circuit
assembly, function, and regulation.
Several mutations in CDKL5, including missense, point, frameshift, and splicing
mutations, have been identified in CDKL5 disorder in humans. These mutations are
predominantly localized in the kinase domain, suggesting that the ability of the protein to
function kinase is critical. Our data demonstrating the localization of CDKL5 in
synaptosomes and nuclei is consistent with data from other labs(19, 30, 34, 55). Thus, it
is likely that the predominant kinase substrates of CDKL5 are localized to synapses and
nuclei. While some of these substrates, including MeCP2, Dnmt1, and amphiphysin1
(25, 53, 55) have been identified, many likely remain to be identified. It is likely that the
dynamic phosphorylation of these substrates in different cellular compartments
contributes to the functional roles of CDKL5 in neural circuit function.
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The mTOR signaling pathway(132, 133) in neurons has key roles in a variety of
signaling mechanisms associated with long-term potentiation, long-term depression,
learning and memory, neuronal survival, differentiation, and morphogenesis(132). We
note that previous studies have demonstrated a reduction in the levels of pmTORS2448
in whole brain lysates of the complete null CDKL5 mouse model(82). While our data
show a slight trend towards reduction of pmTORS2448 in the CDKL5 Fl/Y CaMKIIα-Cre
mouse cortex, these do not reach significance, suggesting that regional and neuronal or
cell-type specific mTOR signaling mechanisms may be regulated by CDKL5.
Our data indicate that loss of CDKL5 in glutamatergic neurons of the cortex leads
to a significant reduction in levels of p70 ribosomal S6 protein kinase 1 (p70S6K1) and
its phosphorylated form, p70S6K1T389. The ribosomal protein p70S6K1(134) is a
downstream target of the mTORC1 pathway. P70S6K1 can be phosphorylated at T389
by mTORC1. Phosphorylation of S6K1 by mTORc1 activates S6K1 and subsequently
protein synthesis. One of the substrates of activated S6K1 is ribosomal protein S6, a
component of the 40S ribosome. S6K1 functions have been implicated in a variety of
mechanisms related to neuronal morphology, including axon regeneration(135), and
dendrite morphology(136) and behaviors, including depressive behavior in the prefrontal
cortex(137) and learning, memory, and synaptic plasticity(138). Interestingly, published
studies indicate that loss of CDKL5 in a mouse model leads to reduced S6 Ser240-244
phosphorylation(116), suggesting that deficits in mTOR-dependent translational
regulation may be a key feature of CDKL5 disorder. How the loss of CDKL5 leads to an
alteration in the levels of p70S6K1 remains to be identified; however, these observations
are highly significant and suggest a mechanism by which CDKL5 may regulate
translation via the mTOR pathway. Identifying such mechanisms and the translational
products that are regulated by these mechanisms may have great significance for our
understanding of the molecular pathology in CDKL5 disorder.
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Our data also indicate that the loss of CDKL5 in inhibitory neurons, surprisingly,
does not mirror the effects observed with loss of CDKL5 in excitatory neurons. Unlike,
the alterations in glutamatergic neurons, loss of CDKL5 in GABAergic neurons of the
striatum leads to a trend towards increase in the levels of p70S6K1 with a trend towards
decrease of its T389 phosphorylated form, both of which were not significant. It is
possible that heterogeneity of responses in subtypes of GABAergic neurons may
contribute to these trends; however, these assessments require further experimental
evidence. However, in stark contrast to the data from glutamatergic neurons, the levels
of Rag C were significantly increased in GABAergic neurons with loss of CDKL5. The
Rag family of proteins is GTPases(139). They function as heterodimers of either Rag A
or Rag B with either Rag C or Rag D and switch between engaging GTP and GDP to
form part of a cellular mechanism that allows for nutrient sensing at the level of
lysosomes and connect autophagy to mTORC1 signaling(140, 141). Consequently, the
precise control of this signaling pathway is essential for cells to respond to changing
cellular energy demands. We note that the levels of Rag A and B are unaltered with loss
of CDKL5 in inhibitory neurons, but the levels of Rag C are significantly increased. At the
cellular level, this is likely to lead to an imbalance in the ability of the Rag proteins to
couple nutrient sensing to autophagic mechanisms, leading to deficits in neuronal
metabolism that could impact multiple aspects of neuronal function relevant to the
pathology of CDKL5 disorder, including synaptic physiology(142, 143). The validation of
this model requires in-depth assessments of nutrient sensing and neuronal responses in
the absence of CDKL5 in inhibitory neurons and may lead to great insights into the
molecular pathology in CDKL5 disorder.
Several studies indicate that CDKL5 is localized at excitatory synapses and loss
of CDKL5 perturbs excitatory synaptic structure and function. Multiple mouse models for
CDKL5 have been generated and recapitulate some aspects of the CDKL5 disorder.

53
Complete CDKL5-null mice (exon 6 deletion(84)) exhibit behavioral features similar to
autism and ADHD. Complete CDKL5-null mice (exon 2 deletion(107)) have increased
susceptibility to NMDA-mediated seizures, enhanced anxiety, and altered depressivelike and social behaviors. Another complete null mouse model for CDKL5(82) exhibits
hyperactivity, motor impairments, decreased anxiety, and social behaviors reminiscent of
autism. Interestingly, female heterozygous mice lacking one allele of CDKL5 also display
several behavioral phenotypes including autistic-like behaviors, motor deficits, and
memory and breathing abnormalities(144). These studies confirm that complete loss of
CDKL5 in murine models leads to several behavioral features reminiscent of the human
disorder.
CDKL5 is expressed in both glutamatergic and GABAergic neurons. Mice with
selective loss of CDKL5 in glutamatergic neurons in the forebrain (using Nex-Cre(92))
exhibit a hindlimb clasping phenotype and have some deficits in hippocampal learning
and memory. A similar hindlimb clasping phenotype is observed in mice in which CDKL5
is deleted from a mouse model bearing a floxed allele of CDKL5 using the Emx-Cre line.
Male mice that are null for CDKL5 in GABAergic neurons generated by crossing mice
bearing a CDKL5 floxed allele into the Dlx5/6 Cre line demonstrate decreased
locomotion(94). Based on these data, it is likely that CDKL5 has differential functional
roles in glutamatergic and GABAergic neurons.
Our results with loss of CDKL5 in excitatory neurons of the cortex are consistent
with Western blot data from CDKL5 Y/− hippocampi demonstrating no alterations in total
levels of NR2B and VGLUT1 in the CDKL5 Y/− mice in comparison to control(107).
However, we do observe an increase in the levels of PSD-95 with loss of CDKL5 in
glutamatergic neurons. Our results are in contrast with data(116) demonstrating a
decrease in the levels of PSD-95 in the cortex of CDKL5 Y/− mice. While our data was
obtained from entire cortical lysates, the data in(116) was obtained from the

54
somatosensory cortex. Thus, it is possible that regional differences in the levels of
excitatory synaptic markers exist within the cortex in the absence of CDKL5. Our data
are also in contrast with data from(107) demonstrating no alterations in the levels of
PSD-95 in hippocampal lysates from CDKL5 Y/− mice. Taken together, these data
suggest that loss of CDKL5 may lead to regional differences in excitatory synaptic
markers within the brain and cortex. Further sophisticated electrophysiological and highresolution microscopy studies are necessary to establish such differences.
Our results indicate that loss of CDKL5 in GABAergic neurons of the striatum
does not significantly alter the levels of excitatory synaptic markers. However, similar to
the data from excitatory neurons, these data do not rule out the possibility that synaptic
levels of some of these markers are altered while total levels are not.
Previous studies indicate that mice with complete loss of CDKL5 have reduced
levels of c-fos, a protein encoded by an activity-regulated immediate early gene, in both
excitatory neurons and parvalbumin-positive inhibitory neurons(115). Our data indicate
that loss of CDKL5 in either excitatory or inhibitory neurons does not alter levels of Arc,
an activity-regulated immediate early gene(145), suggesting that loss of CDKL5 may
selectively alter expression of activity-regulated genes that may be relevant to the
pathology of CDKL5 disorder.
We have identified neuron-type specific alterations with loss of CDKL5 in
components of the mTOR signaling pathways and synaptic proteins. Both of these
pathways are critical for neural circuit formation and function. Taken together with
published data, our results suggest that the differential functional roles of CDKL5 in
excitatory and inhibitory neurons may be critical for its functional roles in neural circuit
formation and function and disruptions in these functional roles with loss or mutations in
CDKL5 contribute to the pathology of CDKL5 disorder.
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CHAPTER 2: GENERATION AND BEHAVIORAL CHARACTERIZATION OF A
MISSENSE CDD MURINE MODEL
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Introduction
Mouse models are an often-used tool to characterize and understand molecular
and behavioral phenotypes that are relevant to human disorders. Many knockout,
knockin, and transgenic mice have been developed for use in neurodevelopmental and
epileptic disorders(146). Furthermore, behavioral assays have been developed to
correlate the observed murine phenotypes to that of humans. The ultimate goals of
developing and characterizing such models is to extrapolate findings from these models
to better understand the human disorder and to use these models for preclinical
translational studies.
Initially, mutations in CDKL5 were identified in patients with X-linked infantile
spasms (ISSX)(22) and Rett Syndrome(8). These disorders are characterized by
mutations in the ARX(147) and MeCP2(148) genes, respectively, and as such, mouse
models with these genes mutated or knocked out have been generated. As the clinical
presentation of CDKL5 patients diverted from other similar neurodevelopmental
disorders, mutations in CDKL5 became classified as an independent disorder, CDKL5
Deficiency Disorder (CDD). To better study CDKL5 mutations, several Cdkl5-knockout
mouse models have been generated that result in loss of full-length CDKL5(82, 92-94,
107, 110). Some are constitutive and some are conditional knockouts in either
glutamatergic or GABAergic neurons. One is a missense mutation in the kinase domain
that is effectively protein-null. Thus far, most behavioral and molecular studies of these
models have been conducted in males. One of the most defining characteristics of the
human disorder is early-onset epilepsy. None of the current models recapitulate this
phenotype. However, these models have recapitulated other characteristics of CDD to
varying degrees, including sensorimotor, cognitive, and social deficits. However, the
major limitation of these models is that they do not replicate the nature of the protein
observed in CDD patients. The majority of CDD patients have point mutations that result

57
in the generation of a protein comparable in size to the full length protein or a
prematurely truncated protein and are not null for the CDKL5 protein. A critical
requirement in the field is the availability of mouse models that more accurately reflect
the genetic basis of the disorder and, hence, its clinical presentation.
Most CDKL5 mutations are de novo and do not demonstrate inheritance from
parental alleles. The majority of CDD mutations are nonrecurrent. One of the few
recurring mutations is R175S, occurring in monozygotic twins. To better study the effect
of mutated CDKL5 encoding full-length protein, we generated a murine model containing
a kinase domain missense mutation of a human pathogenic variant, R175S. This model
generates full-length protein in hemizygous males and both hetero- and homozygous
females. Furthermore, CDKL5 R175S males recapitulate key behaviors of human CDD.
Therefore, the CDKL5 R175S murine model may serve as a better tool for study of
missense mutations generating full-length protein. In this chapter, we discuss the
molecular and behavioral characterization of this model and its relevance to the human
disorder.
Experimental Procedures
Animals
All animal experiments were approved by Institutional Animal Care and Use
Committee of the University of Nebraska Medical Center. Mice were housed with 12/12h dark/light cycle with free access to food and water. Only male mice were included in
this study.
Immunoblotting
Mice were anesthetized by isoflurane and brain tissues from the cortex were
dissected out in cold 1× PBS on ice. Tissues were quick-frozen on dry ice and stored at
− 80 °C. For tissue lysate preparation, cold lysis buffer, including 50 mM Tris pH 7.4,
107 mM NaCl, 1% Triton X-100, 0.1% SDS, 1:100 protease inhibitor (Sigma, P8340),
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1:100 phosphatase inhibitor (Sigma, P0044), 5 mM EDTA, and 5 mM EGTA, was added
to the samples before thawing, to minimize nonspecific cleavage by protease. Tissues
were then homogenized by sonication (22–25% amplitude, 2-s sonication for 3–8 times
according to the size of the tissue, with at least 60-s interval between each sonication)
on ice and centrifuged 15,000 rpm for 5 min at 4 °C. Supernatants were loaded on 7.5%
or 10% hand-casted SDS-PAGE, with 15–50 μg of protein per well. Blots were probed
for CDKL5 using the 6680 antibody.
Behavioral Assays
All animal behavioral studies were carried out blinded to genotype. Mice were
allowed to habituate to the testing room for at least 30 mins before the test, and testing
was performed at the same time of day. All animal behaviors were performed on adult
male mice at 3-8 months of age, and the analysis of behavioral data was carried out by a
researcher blinded to genotype. Body weight of mice was recorded weekly throughout
the battery.
Home Cage Monitoring
Twenty-four-hour monitoring in the home cage was conducted. Mice were
housed individually in a custom-designed home-cage system with force plates to
measure temporal and spatial movements. Locomotor activities were monitored for 3
weeks(149).
Open Field
In order to assess locomotion, animals were placed in the corner of a square
arena (49 × 49 cm) and their behavior was monitored for 20 min using a video camera
placed above the center of the arena. A center zone ¼ size of the arena was applied
using EthoVision software (Noldus Information Technology B.V., The Netherlands) to
score time spent at the border of the arena or in the center zone. The test chambers
were cleaned with 70% ethanol between test subjects.
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Novel Object Recognition Test (NORT)
NORT was carried out to evaluate short-term memory. Each animal was allowed
to explore in a square arena (49 × 49 cm) for 10 min on day 1. The two following days the
mouse was given a 15-minute trial to explore in the arena with two objects placed in
opposite and equidistant positions. On day 4 one of the acclimated objects was replaced
with a novel object of similar size. Animals were allowed to explore the arena for 15 min.
Facing an object within 2 cm and touching an object were taken as measure of object
exploration behavior. The object and arena were cleaned with 70% ethanol between
each trial to eliminate olfactory cues between mice. Each day mice were recorded with
an overhead camera and the videos were analyzed with EthoVision software. Working
memory was evaluated by the recognition index, which was defined as, time exploring
the novel object (or familiar object)/time exploring both objects.
Marble Burying
The marble burying test was performed by placing animals individually in a
home-cage-like environment with a 5-cm depth of unscented standard bedding material
and 20 marbles arranged in a 4 × 5 matrix and left undisturbed for 30 min. The number of
marbles that were at least half buried at the end of the trial was counted.
Accelerating Rotarod
Testing was performed at an accelerating linear speed (0–40 rpm within 300 s).
Three testing trials with an intertrial interval of 20 mins to 1 h were performed on day 1.
To assess motor learning, three more trials were performed on day 2. The latency to fall
from the rotating rod were recorded for each trial.
Statistics
All the statistical tests were performed on Prism 8 (GraphPad). Student’s twotailed t-test was performed on for all behavioral assays.
Results

60
Generation and Validation of CDKL5 R175S Mouse Model
We generated a novel murine model bearing a single nucleotide mutation from a
G to C, in the CDKL5 gene using CRISPR-Cas technology(150). This mutation results in
the change of amino acid 175 in the CDKL5 protein from an arginine (R) to a serine (S),
a site is conserved in the human CDKL5 (Fig 6A, B). The R175S mutation is localized
within the kinase domain of CDKL5 (Fig 6C). We confirmed the transmission of the allele
by PCR analysis (Fig 6D). Expected X-linked patterns of inheritance were observed in
both males and females. Sanger sequencing of the locus confirmed that the genomic
nucleotide was altered as expected (Fig 6E). Further, Western blot analysis of the
CDKL5 protein from wild-type and mutant males indicated that the R175S mutant form of
CDKL5 resulted in the generation of a protein that is comparable in length to the fulllength protein (Fig 6F).
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Figure 6. Generation and validation of CDKL5 R175S mouse model. A) Sequence
homology between human and mouse within the kinase domain showing the amino acid
arginine residue of a CDD pathogenic variant and site of mouse model generation. B)
Nucleotide sequence indicating G to C change for R175S missense mutation. C) Model
of location of R175S within kinase domain of full-length protein. D) PCR of wild-type,
hemizygous males, heterozygous females, and homozygous female mouse tail lysates.
E) Sanger sequencing confirming nucleotide sequence of R175S mutant mice. F)
Western blot of cortical lysates from wild-type and R175S/Y males used for behavioral
assays, indicating presence of full-length protein in R175S/Y mice.
Weight Differences Between Wild-Type and Mutant Mice Across Length of
Behavioral Battery
Two founder lines bearing the R175S allele were generated and grouped into two
respective cohorts termed “blue” and “yellow.” Throughout the course of the behavioral
battery we weighed mice weekly. Both at younger and older ages in the battery and for
both founder lines, mutant R175S mice trended towards an increase in weight relative to
wild-type mice, that reached significance in one cohort at older ages (Fig. 7A).
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Figure 7. Weight differences between wild-type and mutant mice across length of
behavioral battery. A) Comparison of wild-type and mutant R175S/Y mice from two
cohorts, termed “blue” and “yellow,” during the early and late weeks of the behavioral
battery. Data presented ± SEM. **P<0.005, Students t-test with Welch correction.
Locomotor Deficits of R175S/Y Mice in a Home-cage Environment
To reduce handling and anxiety we began the behavioral battery with the least
stressful assay of home-cage monitoring. Test mice were introduced to a home-cage on
force plates to record daily movements for three weeks. For both cohorts R175S mice
moved less than wild-type mice on a daily average (Fig. 8C, D), with most of this deficit
occurring during the dark cycle (Fig. 8A, B). R175S mice also have less locomotion (Fig.
8E, F), fewer locomotor onsets (Fig. 8G, H), and slower locomotor speed (Fig 8.I, J) than
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wild-type controls. Interestingly, there were no differences between wild-type and R175S
mice in locomotor bout duration (Fig. 8K, L) indicating the observed locomotor deficits
may not be due entirely to motor impairments.
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Figure 8. Locomotor deficits of R175S/Y mice in a home-cage environment. A, B)
Locomotion measured in meters of wild-type and mutant R175S/Y mice from two
separate cohorts, termed “yellow” or “blue,” during dark and light cycles. C, D) Daily
movement of wild-type and R175S/Y mice from each cohort. E, F) Locomotion of wildtype and R175S/Y mice from each cohort. G, H) Locomotor onsets per hour of wild-type
and R175S/Y mice from each cohort. I, J) Speed of movement of wild-type and R175S/Y
from each cohort. K, L) Locomotor bout duration of wild-type and R175S/Y mice from
each cohort. Data presented ± SEM.
Increased Anxiety-related Behaviors in Open-Field Environment
One key characteristic in CDD is autistic- and anxiety-related behaviors. To
assess this in our mutant mice, we performed an open field environment test and
analyzed the video recordings with EthoVision software. With the software we created a
center zone to measure thigmotaxis, a measure of anxiety and tendency of mice to stay
near walls in an open environment(151), of wild-type and R175S mice. R175S mice
spent less time in the center zone than wild-type controls (Fig. 9A, B), as well as
entering the center zone less when normalized to total movement, compared to wild-type
animals (Fig. 9C, D). Collectively indicating R175S mice have anxiety-related behavior.
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Figure 9. Increased anxiety-related behaviors in open field environment. A, B)
Time spent in center of open field arena for cohort 1 & 2 mice, respectively. C, D)
Number of center zone entries normalized to total distance moved for cohort 1 & 2 mice,
respectively. Data presented ± SEM, *P < 0.05, **P < 0.005, ***P < 0.0005, Student’s ttest with Welch correction; N = 6 (WT), N=8 (R175S) for cohort 1; N=11 (WT), N=9
(R175S) for cohort 2; age 3-8 months.
R175S/Y Display Impaired Hippocampal Learning and Memory
Intellectual impairments are another key characteristic of CDD. The novel object
recognition test (NORT) is used as a measure of non-social memory in rodent
models(152). In this assay wild-type mice tend to spend more time with novel objects as
opposed to familiar objects, indicating some degree of memory. This was recapitulated
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in our control mice in both cohorts (Fig. 10A, B). However, R175S had conflicting
phenotypes between cohorts. Cohort 2 R175S showed a trend towards hippocampal
impairments, but further studies are needed to confirm this phenotype.

Figure 10. R175S/Y display impaired hippocampal learning and memory. A, B)
Measure of recognition index (time spent at one object/total time at both objects) for
wild-type and R175S/Y in cohort 1 & 2, respectively. Data presented ± SEM, *P < 0.05,
**P < 0.005, ***P < 0.0005, Student’s t-test with Welch correction; N = 7 (WT), N=8
(R175S) for cohort 1; N=9 (WT), N=11 (R175S) for cohort 2; age 3-8 months.
R175S/Y Show Reduced Marble Burying Behavior
Stereotypies such as rocking and hand flapping are coordinated repetitive
behaviors that are commonly observed in autism and other neurodevelopmental
disorders, including CDD(153). To assess stereotypic behavior in our mouse models we
used a marble-burying assay. Marble burying has been used as both a measure of
repetitive behavior and novelty-induced anxiety, though it is best believed to be used for
stereotypies(154, 155). Despite observed anxiety of R175S mice in the open field assay,
both cohorts buried fewer marbles than wild-type mice (Fig. 11A, B). This phenotype has
been observed in other autism mouse models(144, 156) and may be explained by
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observed motor and exploratory deficits. Further analysis of the data may provide better
insights.

Figure 11. R175S/Y show reduced marble burying behavior. A, B) Number of
marbles buried between wild-type and R175S/Y mice for two cohorts. Data presented ±
SEM, *P < 0.05, **P < 0.005, ***P < 0.0005, Student’s t-test with Welch correction; N = 7
(WT), N=8 (R175S) for cohort 1; N=9 (WT), N=11 (R175S) for cohort 2; age 3-8 months.
R175S/Y Display Impaired Motor Learning
To further assess the movement deficits observed in the home-cage monitoring
environment, we performed an accelerating rotarod assay, in which mice are placed on
a spinning rod that accelerates over the course of five minutes. The time mice spend on
the rod is measured as latency to fall. When used over multiple trials and multiple days,
the accelerating rotarod can assess both motor coordination in the early trials and motor
learning in the later trials. Only the second cohort of R175S mice displayed motor
learning deficits relative to wild-type mice (Fig. 12B). R175S did show impaired motor
coordination on day 1 (trials 1-3), though they improved at a similar rate to wild-type
animals. The first cohort of mice (Fig. 12A) displayed no difference between genotypes.
This is most likely due to malfunction of the testing apparatus. Further studies are
necessary to confirm this assessment.
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Figure 12. R175S/Y display impaired motor learning. A, B) Latency to fall from an
accelerating rotarod over 6 trials (3 per day) between wild-type and R175S/Y mice from
two cohorts. Data presented ± SEM, *P < 0.05, **P < 0.005, ***P < 0.0005, Student’s ttest with Welch correction; N = 6 or 7 (WT), N=8 (R175S) for cohort 1; N=9 (WT), N=11
(R175S) for cohort 2; age 3-8 months.
Alterations in Baseline and Ketamine-induced Oscillations in CDKL5 R175S Mice
The most defining characteristic of CDD is early-onset epilepsy. Thus far, none of
the generated CDKL5 mouse models exhibit spontaneous seizures, though several
models display increased seizure susceptibility(93, 107). One potential cause of epilepsy
and other developmental disorders, such as autism, is aberrant neural synchrony.
Gamma oscillations have been observed before and during epileptic events in humans
and rodents and have been implied in working memory and cortical processing. Another
related potential cause of epilepsy is an imbalance between excitation and inhibition in
neural networks. Inhibitory neurons largely regulate the oscillatory function of the
network. Ketamine, a non-competitive NMDAR antagonist, blocks excitation of inhibitory
neurons, which disrupts the excitation/inhibition balance and alters neuronal oscillations.
While spontaneous seizures have not yet been observed in our model, we decided to
determine if R175S mice have altered neuronal oscillations and susceptibility to
seizures. R175S mice have similar baseline power spectrum to wild-type mice (Fig.
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13A). When injected with ketamine, R175S male mice have a smaller power increase
than wild-type mice, indicative of impaired NMDAR function.

Figure 13. Alterations in baseline and ketamine-induced oscillations in CDKL5
R175S mice. A) The baseline power spectrum of WT (blue) and R175S (red) mice
before drug administration was determined by ECoG; SEMs are shown by light shading.
B) Ratio of baseline oscillatory power, R175S mice / WT mice, as a function of
frequency. C) The ketamine-induced increase in oscillatory power at different
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frequencies is expressed as the average % increase over the preceding drug-free
baseline for WT (blue line, n = 10) and R175S (red line, n = 9). SEMs are shown by light
shading.
Discussion
The use of animal models in the study of neurological disorders is particularly
relevant as they permit the use of behavioral characterization assays to determine the
correlation to human disorders. Additionally, they allow the testing of novel therapeutic
agents in vivo to understand molecular mechanisms underlying disorders. Most
mutations in CDKL5 occur within the kinase domain and are not protein-null. In contrast,
all the currently generated mouse models are protein-null. To better understand CDKL5
function in the presence of mutated, but full-length CDKL5, we generated a mouse
model bearing the R175S mutation and characterized the behavior of male mice. In the
present study, we found that R175S male mice recapitulate several behavioral aspects
of CDD including autistic-like behaviors, motor impairments, and learning and memory
disabilities. These phenotypes are some of the core characteristics in human patients
with CDD(157-159), thus presenting the R175S mouse model as a viable candidate for
molecular and therapeutic studies.
On average, R175S male mice trended towards an increase in bodyweight
relative to wild-type mice throughout the length of the behavioral battery. In one cohort,
the observed increase in bodyweight reached significance when mice reached the age
of 28-33 weeks (Fig. 7). This may be explained by the reduction in locomotion of R175S
mice in a home-cage environment (Fig. 8). Corroborating this data is the impaired motor
learning and coordination observed in one cohort of R175S mice in the accelerating
rotarod test (Fig. 12). This is also consistent with other CDKL5 murine models(82, 84,
94, 131) and with the gross and fine motor skills impairments presenting in CDD
patients(13). Mouse models of autism and related disorders often display stereotypic
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behaviors that are representative of the human disorder. This is also the case for CDD
patients(13, 37) and some CDKL5 mouse models(82, 84). R175S mice in our studies
showed a reduction in the number of marbles buried compared to wild-type animals (Fig.
11). This lack of stereotypic marble burying in R175S mice may be explained by reduced
locomotion or from decreased interest towards the environment. Alternatively, repetitive
behavior can often be attributed to increases in anxiety. To assess the degree of anxiety
in R175S mice, we performed an open field test and measured the number and duration
of center zone entries between wild-type and R175S mice. For both cohorts, R175S
mice showed a reduction in the number of entries and time spent in the center of the
arena (Fig. 9), indicating they have anxiety-related behaviors.
Another key feature of CDD is intellectual disability. Learning and memory
impairments have been a consistent feature in other CDKL5 models(82, 84, 117, 160162). R175S mice recapitulated this phenotype in the NORT by spending less time with
the novel object, though this was not reproduced in both cohorts (Fig. 10).
The other main characteristic of CDD patients is the presence of early-onset
seizures. Thus far, CDKL5 mouse models have not been able to recapitulate this
phenotype through spontaneous seizures. However, some studies have examined the
response of CDKL5 mouse models to induced seizures(93, 107). We also examined
seizure susceptibility and oscillatory function in R175S mice and found they have
reduced power increase in response to ketamine treatment, indicating they have
impaired NMDAR function.
In conclusion, we have generated a missense mouse model that translates fulllength protein and recapitulates several key characteristics of the human disorder, thus
serving as a novel model for further molecular and therapeutic studies.
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DISCUSSION
CDKL5 Deficiency Disorder (CDD) is a neurodevelopmental disorder
accompanied by epilepsy, autistic-related behavior, and motor and intellectual
impairments. There is currently no cure for the disorder and, thus, presents a need to
develop approaches that will lead to therapy.
Our studies indicate that (1) CDKL5 is well expressed in the regions of the brain
that are relevant to the clinical phenotypes of CDD, (2) loss of CDKL5 leads to neurontype (glutamatergic and GABAergic) specific alterations in components of the mTOR
pathway and synaptic markers, and (3) a mouse model bearing a human CDD mutation
recapitulates key behavioral phenotypes associated with the disorder. While our studies
are an important step forward for CDD, several questions remain, both in terms of basic
studies and therapy.
Several substrates and pathways involving CDKL5 have been identified, but
further studies are necessary to clarify the diverse functions of CDKL5 that are disrupted
in CDD. A consensus sequence has been proposed(43) and substrates identified in
nonneuronal cells. Additional studies will elucidate substrates in neurons and whose
phosphorylation, i.e. function, is perturbed in models possessing mutant forms of
CDKL5, such as our R175S model.
Several mouse models have been generated and characterized behaviorally to
confirm the phenotype observed in humans is recapitulated in the models. Additionally,
the generation and validation of other mouse models that more accurately represent the
genetic nature of CDD, such as our R175S model, is a need in the field. As CDKL5
reaches highest expression levels during early development, the generation of inducible
models would also be valuable to determine CDKL5 function at different timepoints(163).
One defining feature of CDD, namely epilepsy, is not recapitulated in any of the currently

74
available models. Therefore, generation of a model that recapitulates this phenotype
would be of great value for preclinical and clinical translational studies.
Our studies indicating that loss of CDKL5 perturbs mTOR signaling mechanisms
and synaptic mechanisms are consistent with studies from other labs(82). We propose
that pharmacological approaches that restore aberrations in this pathway may be
beneficial in CDD.
The ultimate goal of understanding CDD and CDKL5 function is to develop
targeted therapies at the molecular level. Thus far, therapeutic interventions have been
aimed at ameliorating the epileptic phenotype through the use of cannabis and
cannabidiol(164-166) and vagal nerve stimulation(167, 168). One drug that has been
used in the treatment of epilepsy disorders and in the study of CDKL5 is pregnenolone,
a neurosteroid that restores the microtubule association of CLIP170 and rescues
morphological deficits(69). Current clinical trials are ongoing for the use of its derivative,
Ganaxolone, in the treatment of CDD. Another epileptic drug fenfluramine is also in
clinical trials. It is shown to act in serotonin reuptake and glutamate modulation(169).
Treatment of CDKL5 mouse models with the drugs tianeptine, IGF-1, and the GSK3β
inhibitor SB216763 have also been shown to rescue the observed phenotypes(77, 116,
161). Another clinical trial is using TAK-935, an NMDAR modulator. The efficacy and
value for several of these ongoing CDD therapies is likely to be ascertained over the
next few years.
Other studies are utilizing read-through drugs to ameliorate CDKL5 functional
deficits. Several nonsense mutations in CDD result in prematurely truncated protein
products. Aminogylcoside read-through drugs, such as gentamicin and geneticin,
promote the readthrough of premature stop codons and can result in increased levels of
full-length protein. HEK293 cells transfected with either CDKL5 R59X or R134X show
increased expression of full-length CDKL5 when treated with increasing concentrations
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of gentamicin or geneticin. Other nonsense mutations, Q347X, E364X, and S855X, also
show increased expression of full-length CDKL5, though to varying degrees. R59X,
R134X, and R550X CDKL5 mutations have reduced catalytic activity when expressed in
HEK293 cells, measured by phospho-TEY levels, that is restored with geneticin, though
they remain hypomorphic. Changing these constructs to point mutations results in
reduced kinase activity via phospho-TEY levels for R59X and R134X, mutations within
the kinase domain, while R550X kinase activity was not affected. These mutations are
also mislocalized in HeLa cells. In HEK293 cells treated with geneticin, localization was
similar to wild-type(170). A non-aminoglycoside read-through drug, Alaturen, is in clinical
trials for treatment of CDD, though it was shown to be ineffective in vitro(170). This may
be due to an inefficiency in crossing the blood-brain-barrier(171). Together, this indicates
that read-through drugs may be a viable candidate for treatment in CDD, though kinase
function is only slightly restored.
Gene replacement and protein substitution therapies have also been shown to be
effective in the treatment of mice lacking CDKL5(162, 172). Additionally, CRISPR-Cas
mediated gene editing has revolutionized genetic editing and has potential for therapy in
CDD(173, 174).
Thus, we are currently at an exciting stage in CDD research. The availability of
several tools and technologies, including specific antibodies, mouse models and
advanced imaging and genome engineering tools holds great promise in allowing major
basic research and clinical translational strides for CDD.
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